

G OPEN ACCESS

Citation: Shimamoto T, Yamamichi N, Gondo K, Takahashi Y, Takeuchi C, Wada R, et al. (2020) The association of *Helicobacter pylori* infection with serum lipid profiles: An evaluation based on a combination of meta-analysis and a propensity score-based observational approach. PLoS ONE 15(6): e0234433. https://doi.org/10.1371/journal. pone.0234433

Editor: Paolo Magni, Università degli Studi di Milano, ITALY

Received: January 7, 2020

Accepted: May 25, 2020

Published: June 8, 2020

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0234433

Copyright: © 2020 Shimamoto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

RESEARCH ARTICLE

The association of *Helicobacter pylori* infection with serum lipid profiles: An evaluation based on a combination of meta-analysis and a propensity score-based observational approach

Takeshi Shimamoto^{1,2}, Nobutake Yamamichi^{2*}, Kenta Gondo², Yu Takahashi², Chihiro Takeuchi², Ryoichi Wada¹, Toru Mitsushima¹, Kazuhiko Koike²

1 Department of Medical Statistics and Information, Kameda Medical Center Makuhari, Mihama-ku, Chiba, Japan, 2 Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan

* nyamamic-tky@umin.ac.jp

Abstract

Background

Several previous studies have suggested that *Helicobacter pylori* (*H. pylori*) infection affects the serum lipid profile. However, it remains controversial and the mechanism has not been elucidated. The purpose of this study is to use an epidemiological perspective to evaluate the association between *H. pylori* infection and the serum lipid profile.

Methods

Multivariate analysis was performed using the data of serum lipid profile, infection status of *H. pylori*, fitness/lifestyle habits, and various subjects' characteristics which were derived from the 15,679 generally healthy individuals in Japan. The average treatment effects (ATEs) of *H. pylori* infection on the serum lipid profile were estimated using augmented inverse probability weighting (AIPW). A meta-analysis was also performed using the 27 studies worldwide in which the status of *H. pylori* infection and at least one serum examination value (high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), or triglyceride (TG)) were described.

Results

The ATEs determined with AIPW showed that *H. pylori* infection has significant positive effects on LDL-C and TC (ATE (95% confidence interval [95%CI]) = 3.4 (2.36–4.49) and 1.7 (0.58–2.88), respectively) but has significant negative effects on HDL-C and TG (ATE (95% CI) = -1.2 (-1.74 to -0.72) and -3.5 (-5.92 to -1.06), respectively). The meta-analysis to estimate the association between *H. pylori* infection and the serum lipid profile revealed that *H. pylori* infection is positively associated with LDL-C, TC, and TG (standardized mean

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

Abbreviations: Alb, Albumin; ALP, Alkaline Phosphatase; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; BMI, Body Mass Index; DBP, Diastolic Blood pressure; ES, Effect Size; FBG, fasting blood glucose; Hb, hemoglobin; HbA1c, hemoglobin A1c; Hct, hematocrit; HDL-C, high-density lipoprotein cholesterol; LDL-C, lowdensity lipoprotein cholesterol; MCH, Mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin; MCV, Mean Corpuscular Volume; PLT, platelet; RBC, Red Blood Cell; SBP, Systolic Blood Pressure; T-Bil, Total Bilirubin; TC, total cholesterol; TG, triglyceride; TP, Total Protein; UA, uric acid(serum); WBC, White blood cell. difference [SMD] (95%CI) = 0.11 (0.09–0.12), 0.09 (0.07–0.10) and 0.06 (0.05–0.08), respectively) and negatively associated with HDL-C (SMD = -0.13 (-0.14 to -0.12)).

Conclusion

Both our multivariate analyses and meta-analysis showed that *H. pylori* infection significantly affects the serum lipid profile, which might lead to various dyslipidemia-induced severe diseases like coronary thrombosis or cerebral infarction.

Background

More than half of the world's population is presumed to be chronically infected with *Helicobacter pylori* (*H. pylori*) [1]. The prevalence of *H. pylori* is particularly high in East Asian countries such as Japan, China, and South Korea [1,2], and a variety of *H. pylori* impacts on the upper gastrointestinal tract have been widely reported [3,4]. Recently, the effect of *H. pylori* infection on the entire body has drawn considerable attention. For example, several studies have reported an association between *H. pylori* infection and extragastric diseases, such as immune thrombocytopenic purpura, idiopathic sideropenic anemia, and vitamin B12 deficiency [5–7]. Among such extragastric disorders, an effect of *H. pylori* on the lipid profile is one of the most important concerns, especially when considering the very high prevalence of *H. pylori* infection and dyslipidemia all over the world [8]. In recent years, several studies have reported that *H. pylori* infection is associated with the serum lipid profile [9–11], but these findings are considered controversial. Concerning the association between *H. pylori* infection and serum lipid profile, we speculate several mechanisms may be responsible for changes in blood lipid regulation.

One idea is based on the effects of *H. pylori* infection upon the digestive system. A lowgrade inflammatory state caused by chronic *H. pylori* infection may interfere with the absorbance of nutrients and could influence the occurrence or evolution of various extragastric diseases. Ghrelin and leptin, both of which are body weight-regulating peptides produced and secreted primarily from the gastric mucosa [12,13], may also play critical roles in this association. Several studies have reported that mucosal atrophy of the stomach induced by *H. pylori* infection greatly affects the homeostasis of leptin and ghrelin [14–18]. These facts indicate that *H. pylori* infection can lead to some appetite related disorders and significant change of body weight. We assume that *H. pylori* infection may cause dysregulated absorption of nutrients in the digestive system, contributing to changes in serum lipids.

The change of lipid profiles may also be due to the effects of the inflammatory response system caused by *H. pylori* infection. Several lines of evidence indicate that the secretion of inflammatory cytokines by cells induced by chronic infection of gram-negative bacteria is related to the change of lipid profiles [19–22]. These investigations indicate that *H. pylori* infection may be involved in the change of lipid profiles through a systemic inflammatory response.

Finally, the effects of *H. pylori* infection may also play a critical role in immune function. It is well established that the eradication of *H. pylori* is effective in treating idiopathic thrombocy-topenic purpura (ITP) [23,24]. Furthermore, several studies indicated that a protective effect of *H. pylori* infection against the development of inflammatory bowel disease (IBD) [25]. As ITP and IBD belong to autoimmune diseases, it is possible that *H. pylori* infection may impact the systemic immune system. Furthermore, several studies also suggest that autoimmune disease is associated with the changes in the lipid profile. For example, rheumatoid arthritis (RA),

one of the most common autoimmune diseases, is related to alterations in the lipid profile. The high inflammatory burden of the RA patients was reported to be associated with the low level of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and total cholesterol (TC) [26–28]. Thus, we assume that autoimmune abnormality caused by *H. pylori* may have an adverse effect on the serum lipid profile.

For all the aforementioned reasons, we have decided to evaluate the association between *H. pylori* infection status and the serum lipid profiles. Even if the association is not strong, it must be clinically important because both *H. pylori* infection and dyslipidemia are very common disorders, and also because a disordered serum lipid profile can lead to severe life-threatening diseases like coronary thrombosis or cerebral infarction [8]. The prevalence of dyslipidemia has been increasing in Japan according to estimates by the Ministry of Health, Labour and Welfare [29], but a similar trend is observed in many nations and has become a worldwide public health problem [30].

The purpose of this investigation was to evaluate the effects of *H. pylori* infection on the serum lipid profiles based on detailed analyses from an epidemiological perspective.

Methods

Study population and ethical approval

This study was approved by the ethics committees of the University of Tokyo, and written informed consent was obtained from each participant before study participation according to the Declaration of Helsinki. The study participants were 19,549 adults with no missing data who underwent a comprehensive medical examination at Kameda Medical Center in Makuhari from January 4 to December 28, 2010. After participants with missing values were omitted, participants with prior gastric surgery (207), taking proton pump inhibitors and/or histamine 2 receptor antagonists (881), having past history of *H. pylori* eradication (1,470), and those taking lipid-lowering drugs (1,312) were further excluded from the investigation, since such confounding factors might adversely affect accurate analysis (Fig 1). The final participants were 15,679 being composed of 8,776 men (mean age 49.6 (9.4) years, range 19–86 years) and 6,903 women (mean age 48.3 (8.9) years, range 20–87 years). In this study, all the participants were asked to respond to the detailed questionnaire (see below), and a serum anti-*H. pylori* IgG antibody test conducted.

Questionnaires

The Ministry of Health, Labour and Welfare of Japan provided specific health checkups and counseling guidance based on scientific grounds in April 2007, through a program initially started in the fiscal year 2008 [31–33]. We used a part of the questionnaires for fitness and dietary habits included in the medical care system. We asked about fitness habits: "Are you in a habit of doing exercise to sweat lightly for over 30 minutes a time, twice weekly, for over a year?" and "In your daily life, do you walk or do an equivalent amount of physical activity more than one hour a day?". We also surveyed dietary habits: "Is your eating speed quicker than others?", "Do you eat supper 2 hours before bedtime more than three times a week?", "Do you eat snacks after supper more than three times a week?", and "Do you skip breakfast more than three times a week?". We further surveyed weight controls with the question "Have you gained over 10 kg from your weight at age 20?" and "Did you gain or lose over 3 kg during the past year?". In addition to the aforementioned questions, we analyzed answers for two questions as follows: i) "How often do you drink alcohol in a week?" and ii) "Do you have a habit of smoking?". The answers for the question i) were selected from five classifications (never, seldom, sometimes, often, and always), which were further categorized into two groups as



Fig 1. Study recruitment flowchart. Of the 19,549 general population participants, we excluded participants with prior gastric surgery (207), those taking proton pump inhibitors and/or histamine 2 receptor antagonists (881), those with a history of *H. pylori* eradication (1,470), and those taking lipid-lowering drugs (1,312). Among the eligible 15,679 participants, the numbers of participants positive and negative for serum *Helicobacter pylori* IgG antibody are shown.

https://doi.org/10.1371/journal.pone.0234433.g001

nominal variables: rarely drinking group (never or seldom) and usually drinking group (sometimes, often, or always). The answers for question ii) were categorized into two groups as nominal variables: current or past habitual smoking (smoker group), and lifelong nonsmoking (nonsmoker group). Alcohol intake and smoking status were measured through self-reporting, and a detailed questionnaire including inquiries about past medical history and current medical history was given to all the participants. Answers filled in by the participants were carefully checked by the nursing staff before being recorded in our study database.

Evaluation of blood chemistry and serum anti-Helicobacter pylori antibody

The measurement of serum lipid levels and serum anti-*H. pylori* antibody was performed on fasting blood samples on the day of blood sampling. The measurement of HDL-C and LDL-C was performed on a direct method. The measurement of TG and TC were performed on the free glycerol elimination method and Cholesterol oxidase method, respectively. The serum anti-*H. pylori* antibody was measured using a commercial EIA kit (E-plate "EIKEN" *H. pylori* antibody II, EIKEN Chemical Co Ltd, Tokyo, Japan). According to the manufacture's instruction, an antibody titer above 10 U/ml was considered *H. pylori*-positive.

Statistical analysis

Using large-scale data from generally healthy individuals, we assessed the current status of the serum lipid profile and *H. pylori* infection in Japan and also evaluated the association between

the two variables. We next conducted a multivariate analysis using all available data to estimate how *H. pylori* infection affects the serum lipid profile. To clarify the effect of *H. pylori* infection on lipid profile, we performed a meta-analysis using all relevant studies published from 1995 to 2016. Finally, we objectively evaluated the estimated results by combining multivariate analysis and meta-analysis. We used JMP 14.2.0, SAS Universal Edition (SAS Institute Inc. Cray, NC, USA) and R statistical package were used for all statistical analyses. The chi-square test was utilized for univariate analysis, multiple logistic regression analysis for multivariate analysis, and an augmented inverse propensity weighted (AIPW) estimator for an estimate of average treatment effects (ATEs).

Estimating effect sizes and ATEs from cross-sectional data

Cohen's *w* was used for univariate analysis. For multivariate analysis, to estimate the effect of H. pylori infection on the serum lipid profile, we used the AIPW with propensity-score (PS) matching was utilized to achieve a better balance between covariates within the matched pairs [34]. The PS was estimated using a logistic regression model that was adjusted to the characteristics of the study participants. Also, to reduce the effect of treatment-selection bias and potential confounding in this cross-sectional study, PS matching was performed by one-to-one pair matching via nearest neighbor matching within a caliper width of 1/5 standard deviation (SD) for the logit of PS without replacement [35]. We used the absolute standardized difference (ASD) to measure covariate balance. An ASD greater than 0.1 represents a meaningful imbalance [36]. The PSs were by defining *H. pylori* infection as a predictive factor and also by defining age, gender, BMI, AST, ALT, ALP, γ-GTP, total bilirubin, TP, Alb, HbA1c, FBG, systolic blood pressure, diastolic blood pressure, UA, RBC, WBC, Hb, Hct, PLT, MCV, MCH, MCHC, smoking, alcohol drinking, fitness habits, and dietary habits as confounding factors. Drinking, dietary habits, and weight controls were treated as yes/no dichotomous variable. With regard to the drinking habits responses, we converted dichotomous variable with "can not drink" and "rarely drink" for "no" and "sometimes", "almost every day" and "every day" for "yes". Other habits and weight controls used the response of yes-no questions. The covariates were selected on the basis of several previous studies [9,37-39].

Meta-analysis

Meta-analysis was conducted according to the PRISMA guidelines. Previous studies used in our meta-analysis were selected on the basis of the inclusion criteria as follows: RCT, case– control or cohort, cross-sectional design, registration in PubMed, CiNii (Scholarly and Academic Information Navigator) or Ichushi Web (NPO Japan Medical Abstracts Society) databases, and description of HDL-C, LDL-C, TC or TG to statistically evaluation of the association between H. pylori infection and the serum lipid profile. A search was performed for combinations of keywords related to *H. pylori* infection and related to the outcome of interest. Concrete keywords used related to *H. pylori* infection were (an asterisk is a replacement for any ending of the respective term; quotation marks indicate that the term was used as a whole, not each word individually): *pylori**, lipid*, "*H. pylori*," "*Helicobacter pylori*," "lipid profile," "lipid metabolism," obesity, dyslipidemia, and arteriosclerosis. The search in both English and Japanese was completed in November 2016. No restrictions were placed on the language or date of publication when searching the electronic databases. Investigations that showed the results of significance but lacked data on the lipid profile were excluded because we could not calculate the risk difference in the meta-analysis.

To obtain an overview of the association between *H. pylori* infection and the serum lipid profile, we performed meta-analyses using the fixed-effects model. We adopted the definition

of the fixed-effects meta-analysis method because we assumed that the treatment effect was the same for each study. To estimate the risk of bias in our meta-analyses, we investigated publication bias by inspection of funnel plots and we applied the Macaskill's linear regression method test for detecting publication bias of meta-analysis [40].

To the evaluation of the validity of the included studies, we assessed the quality of each study using the Risk of Bias Assessment Tool for Nonrandomized Studies (RoBANS) [41]. The evaluation of risk of bias by RoBANS is as follows: "Selection bias caused by the inadequate selection of participants," "Selection bias caused by the inadequate confirmation and consideration of confounding variable," "Performance bias caused by the inadequate measurement of exposure," "Detection bias caused by the inadequate blinding of outcome assessments," "Attrition bias caused by the inadequate handling of incomplete outcome data," and "Reporting bias caused by the selective reporting of outcomes". We made an overall judgment of these elements by three stages including low, high and unclear.

For the unification of a unit of measure for the lipid profile, first, for results presented as mmol/L, we converted the mean and the SD from mmol/L to mg/dL per the International System of Units. Second, for results presented as the median and interquartile range, when we add the median and the first quartile and the third quartile and divided by 3, we estimated the modified mean. Also, we estimated the SD using the method proposed by Xiang [42].

Results

Association between the serum lipid profile and serum anti-*H. pylori* IgG status of the healthy general population in Japan

The levels of the serum lipid profile were compared between the participants seropositive and seronegative for *H. pylori* IgG (Table 1). The *P*-value was calculated by Welch's *t*-test, and

	HDL-C		LDL-C		тс		TG	
	seropositive	seronegative	seropositive	seronegative	seropositive	seronegative	seropositive	seronegative
	N = 4546	N = 11133						
Age (year)								
N (Total/male/female)								
<40	62.9 (15.1)	65.3 (16.3)	114.3 (30.1)	109.2 (29.4)	189.2 (31.3)	185.8 (30.6)	92.1 (61.5)	88.1 (57.4)
N (2539/1328/1211)	1							
40-49	63.6 (15.9)	65.8 (17.1)	122.6 (31.2)	119.0 (31.1)	199.1 (33.6)	197.7 (31.7)	103.3 (81.3)	102.4 (78.9)
N (5685/3068/2617)								
50-59	63.3 (16.4)	66.4 (17.5)	132.4 (29.0)	128.9 (29.5)	209.6 (31.1)	209.1 (31.3)	111.6 (82.0)	110.9 (75.9)
N (5385/3058/2327)								
60≦	63.2 (16.3)	65.7 (16.8)	133.8 (28.9)	130.7 (28.9)	211.2 (31.7)	210.4 (30.6)	110.8 (72.2)	108.1 (67.3)
N (2070/1322/748)								
all ages	63.3 (16.1)	65.9 (17.1)	128.8 (30.3)	121.2 (31.0)	205.6 (32.6)	200.0 (32.5)	107.7 (78.4)	102.7 (73.6)
N (15679/8776/6903)								
<i>t</i> -value	8	.9	14	4.1	9	9.8	3	.7
df	88	86.7	862	29.6	840	06.3	798	38.6
P-value	<0.001		<0.001		<0.001		<0.001	
effect size	0.	.15	0.	25	0.	.17	0.	07

Table 1. Characteristics of serum HDL-C, LDL-C, TC, and TG categorized on the basis of the status of serum Helicobacter pylori IgG antibody and age groups.

The *P*-value was calculated by Welch's *t*-test. Effect size was calculated by Cohen's *d*. A two-tailed *P*-value less than 0.05 was considered statistically significant. Numbers in parentheses show the SD of the mean.

https://doi.org/10.1371/journal.pone.0234433.t001

effect sizes (ESs) were calculated by Cohen's *d*. The participants with chronic *H. pylori* infection had lower values for HDL-C and higher values for LDL-C, TC, and TG. The associations of the four types of lipid with serum *H. pylori* IgG were all statistically significant(HDL-C: t (8886.7) = 8.9, P < 0.001; LDL-C: t (8629.6) = 14.1, P < 0.001; TC: t (8406.3) = 9.8, P < 0.001; TG: t (7988.6) = 3.7, P < 0.001). Judging from the value of ES, *H. pylori* infection had a substantial effect on LDL-C (ES = 0.25). Conversely, *H. pylori* infection had only small effects on HDL-C, TC, and TG (ES = 0.15, 0.17 and 0.07 respectively).

Concerning gender, H. pylori-positive males were significantly associated with HDL-C, LDL-C, and TC; namely men with chronic H. pylori infection had lower values for HDL-C and higher values for LDL-C, and TC (S1 Table). Men with chronic H. pylori infection had lower values of TG compared with men without it, though the difference between the two was not statistically significant. On the other hand, H. pylori-positive females were significantly associated with all types of lipids; namely, women with chronic H. pylori infection had lower values for HDL-C and higher values for LDL-C, TC, and TG (S2 Table). Men had lower values for HDL-C and TC and higher values for LDL-C and TG compared with women, and there were statistically significant differences between the sexes in all types of lipid (HDL-C: t (14304) = 56.1, P < 0.001; LDL-C: t (14374) = 13.1, P < 0.001; TC: t (14317) = 3.8, P = 0.002;TG: t (14666) = 42.5, P < 0.001). Interestingly, chronic *H. pylori* infection had a large effect on LDL-C and TC for females. The ES of women with chronic *H. pylori* infection in LDL-C was the largest (ES = 0.38) out of all types of lipids (S2 Table). Furthermore, women with chronic H. pylori infection showed a statistical and clinical difference at 0.2, 0.29, and 0.15 in HDL-C, TC, and TG, respectively (S2 Table). In contrast, men with chronic H. pylori infection showed a statistical and clinical difference at 0.13 only in LDL-C out of all types of lipids (S1 Table).

Checking the balance of confounding factors in logistic regression using the standardized difference

The predicted probabilities of *H. pylori*-positivity were calculated via a logistic regression model, using carefully selected covariates as shown in <u>S3 Table</u>. Of the possible 11,133 *H. pylori*-negative participants, 4376 were matched with *H. pylori*-positive participants. Age (ASD:0.614), ALP (ASD:0.191), Alb (ASD:0.185), HbA1c (ASD:0.139), systolic BP (ASD:0.157), diastolic BP (ASD:0.169), UA (ASD:0.107), WBC (ASD:0.127), and smoking habit (ASD:0.127) were considered poorly balanced before matching. However, all the covariates in the estimation of HDL-C, LDL-C, TC, and TG were considered well balanced after PS matching judging from the values of ASD. The covariate balance in the matched population was improved by a matching method; the effect of selection bias and potential confounding in our cross-sectional study was successfully reduced.

Estimation of ATEs and confidence intervals concerning the relationship between *H. pylori* infection and serum lipid profile using AIPW

All the ATEs were estimated using AIPW (Table 2). Our data showed that *H. pylori* infection had positive effects on LDL-C and TC with statistical significance (ATE: 3.4 and 1.7, respectively). In contrast, *H. pylori* infection had negative effects on HDL-C and TG with statistical significance (ATE: -1.2 and -3.5, respectively).

Assessment of the risk of bias of individual studies for performing a metaanalysis

The 33 case–control studies, including our data, were evaluated, and we found that 28 studies fulfilled the inclusion criteria (S4 Table) and 5 studies did not (S5 Table). Consequently, data

	Helicobacter pylori infection	Estimate	SE	95% CI	z-test	P-value
HDL-C	seronegative	65.5	0.16	64.14-65.79	397.5	< 0.001
	seropositive	64.2	0.23	63.78-64.69	279.1	< 0.001
	ATE	-1.2	0.26	(-1.74)-(-0.72)	-4.7	< 0.001
LDL-C	seronegative	122.3	0.30	121.72-122.89	409.4	< 0.001
	seropositive	125.7	0.48	124.79-126.67	261.8	< 0.001
	ATE	3.4	0.54	2.36-4.49	6.3	< 0.001
TC	seronegative	201.1	0.31	200.45-201.65	654.0	< 0.001
	seropositive	202.8	0.52	201.76-203.81	387.3	< 0.001
	ATE	1.7	0.58	0.58-2.88	3.0	0.003
TG	seronegative	105.2	0.86	103.46-106.83	122.6	< 0.001
	seropositive	101.7	1.00	99.69-103.62	101.4	< 0.001
	ATE	-3.5	1.24	(-5.92)-(-1.06)	-2.8	0.007

Table 2. Summary of augmented inverse probability weighting reflecting the effect of *Helicobacter pylori* infection on the serum lipid profile in generally healthy individuals.

The average treatment effect (ATE) shows the effects of *H. pylori* infection on lipid profiles. Seronegative: the augmented inverse probability weighting of response in the absence of *H. pylori*. ATE would be the sample average of seropositive minus seronegative. HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, TC: total cholesterol, TG: triglyceride, χ^2 : the chi-square test statistic, SE: standard error, 95% CI: 95% confidence interval. The *P*-value used for ATE, a two-tailed *P*-value less than 0.05 was considered statistically significant.

https://doi.org/10.1371/journal.pone.0234433.t002

from the 28 studies (67,290 *H. pylori*-positive and 53,859 *H. pylori*-negative) were used in the meta-analysis (S1 Fig).

S2 Fig shows an assessment of the validity of the studies included. We judged the blinding of participants (selection bias), confounding variables (selection bias), and measurement of exposure (performance bias) in several studies as high risk of bias. Conversely, we judged the blinding of outcome assessments (detection bias) as low risk of bias. Furthermore, we judged incomplete outcome data (attrition bias) and selective outcome reporting (reporting bias) as unclear risk of bias. Although exposure measurement is not blinded in every study, we judged a considerably low probability of measurement bias because lipid profile and the diagnosis of *H. pylori* are the mere screening blood tests conducted in clinics and health checkups.

Estimation of the pooled mean ESs and confidence intervals in metaanalyses to examine the association between the serum lipid profiles and *H. pylori* infection

Fig 2 shows the results of the meta-analyses. All results were presented graphically in forest plots, and the diamonds at the bottom show the pooled risk differences for all studies with the 95% confidence interval. As shown in Fig 2A, the meta-analysis of 27 studies showed a significant negative association between *H. pylori* infection and serum HDL-C (standardized mean difference [SMD], -0.13; 95% CI, -0.14 to -0.12; *P* for heterogeneity, <0.01). However, as shown in Fig 2B, the meta-analysis of 22 studies showed a significant positive association between *H. pylori* infection and serum LDL-C (SMD, 0.11; 95% CI, 0.09 to 0.12; *P* for heterogeneity, <0.01). Similarly, as shown in Fig 2C, the meta-analysis of 27 studies showed a significant positive association between *H. pylori* infection and serum TC (SMD, 0.08; 95% CI, 0.07 to 0.09; *P* for heterogeneity, <0.01). Further, as shown in Fig 2D, the meta-analysis of 25 studies showed a significant positive association between *H. pylori* infection and serum TC (SMD, 0.08; 95% CI, 0.07 to 0.09; *P* for heterogeneity, <0.01). Further, as shown in Fig 2D, the meta-analysis of 25 studies showed a significant positive association between *H. pylori* infection and serum TG (SMD, 0.06; 95% CI, 0.05 to 0.08; *P* for heterogeneity, <0.01). Altogether, our meta-analyses showed a

(Δ)	Source	SMD (95% CI)	(B)	
(\neg)	Niemela S. 1996 (control)	-0.37 [-0.74; 0.00]		
	Niemela S. 1996 (Coronary heart disease)	-0.10 [-0.48; 0.28] +		
	Minami J. 2002	-0.64 [-0.85; -0.42] <		
	Chimienti G. 2003 (CagA(+))	-0.09 [-0.44; 0.26] -		SMD (95% CI)
	Chimienti G. 2003 (CagA(-))	-0.14 [-0.48; 0.20]	→ Minami J. 2002	0.00 [-0.21; 0.21]
	Sung KC. 2005	-0.12 [-0.14; -0.10]	Chimienti G. 2003 (CagA(+))	0.20 [-0.15; 0.55]
	Saijo Y. 2005	-0.16 [-0.23; -0.09]	Chimienti G. 2003 (CagA(-))	0.41 [0.07; 0.75]
	Osawa H. 2005	-0.39 [-0.72; -0.05]	Sung KC. 2005	0.09 [0.07; 0.10]
	Longo-Mbenza B. 2007	-0.71 [-1.00; -0.42] <	Yura A. 2007	3.52 [3.17; 3.86]
	Kongara T. 2008	-3.69 [-4.26, -3.53]	Kucukazman M 2009	0.39 [0.12: 0.66]
	Kugukatman M 2009	0.14 [0.13: 0.40]	lie EZ 2009	0.01 [0.12: 0.14]
	Jia EZ 2009	-0.03 [-0.16] 0.10]	Aksov H 2009 (Preeclamosia)	122 [0.49 195]
	Aksov H 2009 (Preeclamosia)	0.54 [-0.15: 1.24]	Aksov H. 2009 (Normal pregnancy)	044[-0.30: 1.18]
	Aksov H. 2009 (Normal pregnancy)	0.44 [-0.30: 1.18]	→ Satoh H. 2010	0 13 [0 08: 0 19]
	Satoh H. 2010	-0.14 [-0.20; -0.09]	Huang B. 2011 (CagA(+))	0.83 [0.37; 1.28]
	Huang B. 2011 (CagA(+))	0.51 [0.06; 0.95]	Huang B. 2011 (CagA(-))	0.65 [0.21; 1.09]
	Huang B. 2011 (CagA(-))	0.42 [-0.01; 0.86]	Matsummura K. 2011	0.03 [-0.19; 0.26]
	Matsummura K. 2011	-0.14 [-0.36; 0.08] ++++++++++++++++++++++++++++++++++++	Kim HL. 2011	0.54 [0.35; 0.73]
	Kim HL. 2011	-0.02 [-0.20; 0.17] + +	Saad Al-Fawaeir. 2013	0.23 [-0.02; 0.48]
	Saad Al-Fawaeir. 2013	-0.24 [-0.49; 0.01]	Gerig R. 2013	0.09 [-0.17; 0.35] + + + + + +
	Gerig R. 2013	-0.17 [-0.42; 0.09] ++++++++++++++++++++++++++++++++++++	Vafaeimanesh J. 2014 (Nondiabetic)	0.09 [-0.18; 0.35]
	Yamamoto R. 2013 (male)	-0.10 [-0.22; 0.02]	Vafaeimanesh J. 2014 (Diabetic)	0.18 [-0.10; 0.47] ++
	Yamamoto R. 2013 (female)	-0.17 [-0.27; -0.07]	Karpouza A. 2014	-1.75 [-2.15; -1.35] <
	Vafaeimanesh J. 2014 (Nondiabetic)	0.12 [-0.15; 0.38]	→ Chen LW. 2015	0.07 [-0.07; 0.21]
	Vafaeimanesh J. 2014 (Diabetic)	-0.31 [-0.59; -0.02]	Chen TP. 2015 (male)	0.20 [0.09; 0.30]
	Lu C. 2014	-0.16 [-0.36; 0.04]	Chen TP. 2015 (female)	0.24 [0.11; 0.37]
	Karpouza A. 2014	-1.62 [-2.01; -1.23] <	Sun Y. 2016	0.04 [0.01; 0.06]
	Chen LW. 2015	0.02 [-0.12; 0.16]	Rasmi Y. 2016 (Cardiac Syndrome X)	-0.70 [-1.53; 0.14]
	Chen TP. 2015 (male)	-0.16 [-0.29; -0.08]	Rasmi T. 2016 (Control)	2.67 [2.11; 3.22]
	Sup X 2016		Total	
	Rasmi V. 2016 (Cardiac Syndrome X)	4 55 [5 62: -3 47] <	Heterogeneity: $\gamma^2 = 680.80 (P < 0.1) I^2$	
	Rasmi Y. 2016 (Control)	1.81 [1.33: 2.29]	>	-0.2 -0.1 0 0.1 0.2
	Shimamoto T. 2017	-0.15 [-0.19; -0.12]		Standardised Mean Difference (95% CI)
	Total	-0.13 [-0.14; -0.12]		
	Heterogeneity: $\gamma_{14}^2 = 676.74 (P < .01), I^2 = 95$	%		
(C)	Source	SMD (95% CI)	(D)	
(C)	Source Patel P. 1995	SMD (95% CI) 0.01 [-0.18; 0.21]	(D)	SMD /05% (21)
(C)	Source Patel P. 1995 Niemela S. 1996 (control)	SMD (95% CI) 0.01 [-0.18; 0.21]	→ (D) Source Nerrels S 1995 (control)	SMD (95% CI) 163 (120: 2.05)
(C)	Source Patel P. 1995 Niemela S. 1996 (control) Niemela S. 1996 (Coronary heart disease)	SMD (95% CI) 0.01 [-0.18; 0.21] 0.08 [-0.29; 0.44] -0.06 [-0.43; 0.32] -0.06 [-0.43; 0.32]	(D) Source Normela S. 1996 (Control) Niemela S. 1996 (Coronary heart disea	SMD (95% Cl) 1.63 [120, 2.05] e1.191 0.75: 1.60]
(C)	Source Patel P. 1995 Niemela S. 1996 (control) Niemela S. 1996 (Coronary heart disease) Minami J. 2002	SMD (95% CI) 0.01 [-0.18: 0.21] +	(D) Source Niemela S. 1995 (control) Niemela S. 1996 (control) Niemela S. 1996 (control)	SMD (95% CI) 1.63 (1 20, 2.05) se) 1.19 (0.78; 1.60) -1.40 (2.20; 5.164) <
(C)	Source Patel P. 1995 Niemela S. 1996 (control) Niemela S. 1996 (Coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CagA(+))	SMD (95% CI) 0.01 [-0.16, 0.21] 0.08 [-0.29; 0.44] -0.06 [-0.43; 0.32] -0.20 [-1.04; 0.05] < 0.71 [-0.16; 0.52] -0.71 [-0.16; 0.52] -0.72 [-0.16] <	(D) Source Nienela S. 1996 (control) Nienela S. 1996 (Coronary heart disea Minani J. 2002 Chrimetri G. 2003 (CapA(+))	SMD (95% CI) 1.63 (1 2.0; 2.05) se) 1.19 [0.76; 1.60] -1.80 [2.205; -1.56] < 0.11 [0.25; 0.66] ←
(C)	Source Patel P. 1995 Niemela S. 1996 (control) Niemela S. 1996 (Coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CagA(+)) Chimienti G. 2003 (CagA(-)) Sura KC. 2005	SMD (95% CI) 001 (-0.18, 0.21) 0.06 (-0.29, 0.04) 	(D) Source Niemela S. 1996 (control) Niemela S. 1996 (Coronary heart disea Minarii J. 2003 (CapA(+)) Chmienti G. 2003 (CapA(+))	SMD (95% CI) 1.63 [1 20; 2.05] ae) 1.19 [0.78; 1.60] -1.80 [2.205; -1.56] < 0.11 [0.25; 0.46] ← -27 [0.13; 0.55]
(C)	Source Paile P. 1995 Niemela S. 1996 (control) Niemela S. 1996 (control) Niemela S. 1996 (Control) Chimienti G. 2003 (CagA(+)) Chimienti G. 2003 (CagA(-)) Sung KC. 2005 Sain Y. 2005	SMD (95% Ct) 001 [-018; 0:21] 0.08 [-0.29; 0:44] 	(D)	SMD (96% CI) 1.63 (1 20; 2.05) se) 1.19 (0.78; 1.60) -1.80 (2.05; -1.64) < 0.11 [-0.25; 0.46] 0.21 [-0.13; 0.55] 0.06 (0.04; 0.07)
(C)	Source Patel P. 1995 Niemela S. 1996 (control) Niemela S. 1996 (coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CapA(+)) Chimienti G. 2003 (CapA(-)) Sung KC. 2005 Saije' X. 2005 Saiya Z. 2005	SMD (95% Ct) 0.01 [-0.18; 0.21] 0.08 [-0.29; 0.44] 	(D) Source Niemala S. 1996 (control) Niemala S. 1996 (control) Niemala S. 1996 (control) Niemala S. 1996 (control) Niemala S. 1996 (control) Chimienti G. 2003 (CegA(-)) Chimienti G. 2003 (CegA(-)) Sung KC. 2005 Saijo Y. 2005	SMD (95% CI) 1.63 (1 2.0; 2.05) se) 1.19 (0.78; 1.60) -1.80 (-2.05; -1.56) < 0.11 (0.25; 0.64) 0.21 (-0.13; 0.55) 0.06 (0.04; 0.07) 0.68 (0.01; 0.15)
(C)	Source Patel P. 1995 Niemela S. 1996 (control) Niemela S. 1996 (coronary heart disease) Minami J. 2002 Chrimenti G. 2003 (CagA(+)) Chrimenti G. 2003 (CagA(-)) Sung KC. 2005 Sajo'r. 2005 Osawa H. 2005 Longo-Mencra B. 2007	SMD (95% CI) OO1 (-0.18, 0.21) 0.06 (-0.29, 0.44] 	(D) Source Niemela S. 1996 (control) Niemela S. 1996 (coronary heart disea Minanii J. 2002 Chmierid G. 2003 (CapA(+)) Chmierid G. 2003 (CapA(-)) Sung KC. 2005 Saijo Y. 2005 , Osawa H. 2005	SMD (95% CI) 163 (1 20; 2.05) se) 1.19 [0.78; 1.60] -1.80 (2.205; -1.56) < 0.11 (-0.25; 0.46) ← 0.21 [0.13; 0.55] 0.06 [0.04; 0.07] 0.08 [0.01; 0.15] -1.27 [-163; 0.09] <
(C)	Source Paile P. 1995 Niemela S. 1996 (control) Niemela S. 1996 (control) Niemela S. 1996 (Coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CagA(+)) Chimienti G. 2003 (CagA(-)) Chimienti G. 2003 (CagA(-)) Chimienti G. 2003 (CagA(-)) Chimienti G. 2003 (CagA(-)) Cagawa H. 2005 Longo-Miberza B. 2007 Yura A. 2007	SMD (95% CI) OD1 [-018; 0:21] 	(D) Source Niemala S. 1996 (control) Niemala S. 1996 (control) Niemala S. 1996 (control) Niemala S. 1996 (control) Chimiani G. 2003 (CapA(+)) Chimiani G. 2003 (CapA(+)) Chimiani G. 2003 (CapA(+)) Sung KC. 2005 Saijo Y. 2005 Saijo Y. 2005 , Longo-Mberza B. 2007	SMD (96% CI) 1.63 [1 20; 2.05] se) 1.19 [0.78; 1.60] -180 [2.05; 1.66] <
(C)	Source Patel P 1995 Niemela S. 1996 (control) Niemela S. 1996 (coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CagA(+)) Chimienti G. 2003 (CagA(+)) Sung KC. 2005 Salio'Y. 2005 Cearea H. 2005 Longo-Mherca B. 2007 Yura A. 2007 Kogama T. 2008	SMD (95% Ct) 0.01 [-0.18; 0.21] 0.08 [-0.29; 0.44] 	(D) Source Niemala S. 1996 (control) Niemati G. 2003 (CagA(+)) Chimienti G. 2003 (CagA(-)) Sung KC. 2005 Saljo Y. 2005 Saljo Y. 2005 Coswa H. 2005 Coswa H. 2005 Coswa H. 2005 Yura A. 2007 Yura A. 2007	SMD (95% CI) 1.63 (1 20, 2.05) se) 1.19 (0.78; 1.80) -1.80 (2.05; -1.56) < 0.21 (-0.13; 0.55) 0.06 (0.04; 0.07) 0.08 (0.01; 0.15) -1.27 (-1.63; -0.90) < 0.77 (-0.11; 0.45) -1.18 (0.95; 1.42)
(C)	Source Patel P 1995 Patel P 1995 Niemela S. 1996 (Cortorol) Niemela S. 1996 (Cortorary heart disease) Minami J. 2002 Chrimenti G. 2003 (CagA(+)) Chrimenti G. 2003 (CagA(-)) Sung KC: 2005 Sajo Y. 2005 Osawa H. 2005 Longo-Menorza B. 2007 Yura A. 2007 Kugakar T. 2008 Kucukazman M. 2009 Kucukazman M. 2009	SMD (95% CI) OO1 (-0.18; 0.21) 	(D) Source Niemela S. 1996 (control) Niemela S. 1996 (Coronary heart disea Minand J. 2002 Chrimient G. 2003 (CagA(+)) Chrimient G. 2003 (CagA(+)) Sung KC. 2005 Saijo Y. 2005 Saijo Y. 2005 Charave H. 2005 Yura A. 2007 Yura A. 2007	SMD (#9% C) 1.63 (1 20; 2.05) 1.91 (10.78; 1.60) -1.80 (2.05; 1.56) <
(C)	Source Patel P. 1995 Niemela S. 1996 (Coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CagA(+)) Chimienti G. 2003 (CagA(-)) Sung KC. 2005 Osawa H. 2005 Dawa H. 2005 Longo-Menza B. 2007 Yura A. 2007 Kogawa T. 2008 Kucukazman M. 2009 Jia EZ. 2009	SMD (95% CI) 0.01 [-0.18, 0.21] 0.06 [-0.29, 0.44] 0.06 [-0.43, 0.32] 0.08 [-0.44, -0.61] 0.17 [-0.18, 0.62] 0.047 [0.12, 0.61] 0.08 [-0.43, 0.52] 0.08 [-0.43, 0.52] 0.08 [-0.43, 0.52] 0.08 [-0.43, 0.55] 0.08 [-0.43, 0.47] 0.06 [-0.43, 0.87] 0.06 [-0.44, 0.22]	(D) Source Niemala S. 1998 (control) Niemala S. 1998 (Coronary heart disea Minami J. 2002 Chrimienti G. 2003 (CagA(+)) Chrimienti G. 2003 (CagA(-)) Sung KC. 2005 Sajor Y. 2005 Caswa H. 2005 Longo-Mbenza B. 2007 Yura A. 2007 Kucukuzman M. 2009 Jia EZ. 2009	SMD (85% CI) 1.63 [1 20; 2.06] 1.91 [0.78; 1.60] -1.80 [2.05; -1.64] < 0.11 [-0.25; 0.46] < 0.21 [-0.13; 0.55] 0.06 [0.40; 0.07] 0.06 [0.01; 0.15] -1.27 [-1.63; -0.90] < 1.16 [0.95; 1.42] 0.06 [-0.21; 0.33]
(C)	Source Patel P 1995 Niemela S. 1996 (Control) Niemela S. 1996 (Coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CagA(+)) Sung KC. 2005 Cango-Mberca B. 2007 Yuan A. 2007 Kogawa T. 2008 Kuckuzman M. 2009 Jia EZ. 2009 Aksoy H. 2005 (Corole (Preeclampsia)	SMD (95% C1) 0.01 [-0.18; 0.21] 0.06 [-0.29; 0.44] 	(D) Source Niemela S. 1996 (control) Niemela S. 1996 (control) Niemela S. 1996 (control) Niemela S. 1996 (control) Chimienti G. 2003 (Cap4(+)) Chimienti G. 2003 (Cap4(+)) Sung KC. 2005 Sajig Y. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Sajig Y. 2009 Jia E.Z. 2009 Jia Z. 2007 Jia Z.	SMD (95% CI) 1.63 (1 20; 2.05) sep 1.19 (0.78; 1.60) -1.80 (2.05; -1.56) < 0.01 (0.25; 0.64) -2.21 (0.13; 0.55) 0.06 (0.04; 0.07) 0.08 (0.01; 0.15) -1.27 (1.63; 0.50) < 0.71 (0.11; 0.45) 1.18 (0.95; 1.42) 0.06 (0.21; 0.33) 0.47 (0.23; 1.16) 0.47 (0.23; 1.16)
(C)	Source Patel P. 1995 Niamela S. 1996 (Coronary heart disease) Mirama J. 2002 Chrinerit G. 2003 (CagA(+)) Chrinerit G. 2003 (CagA(-)) Sung KC: 2005 Sajo'r. 2006 Osawa H. 2005 Longo-Mencra B. 2007 Yura A. 2007 Kuckazman M. 2009 Jia E. 2009 Akaoy H. 2009 (Preclampsia) Akaoy H. 2009 (Vormal pragnancy)	SMD (95% CI) OD (1018; 0.21) OD6[-0.29; 0.44] OD6[-0.29; 0.45] OD6[-0.43; 0.22] OD6[-0.43; 0.22] OD7[-0.16; 0.22] OD7[-0.16; 0.22] OD7[-0.16; 0.22] OD7[-0.16; 0.22] OD7[-0.16; 0.22] OD5[-0.22; 0.27] OD5[-0.22; 0.27]	(D) Source Niemela S. 1996 (Corton) Niemela S. 1996 (Coronary heart disea Minand J. 2002 Chrimient G. 2003 (CagA(+)) Chrimient G. 2003 (CagA(-)) Sung KC. 2005 Sajo Y. 2005 Sajo Y. 2005 Charave H. 2005 Longo-Mberza B. 2007 Yura A. 2007 Yura A. 2007 Kuculazman M. 2009 Jia EZ. 2009 Akasy H. 2009 (Preedampsia) Akasy H. 2009 (Preedampsia)	SMD (6% C) 1.63 (1 20, 2.05) 1.91 (10, 72; 1.60) 1.91 (0.72; 1.60) 1.92 (0.72; 1.60) 0.11 (0.25; 0.46) 0.21 (-0.13; 0.45) 0.21 (-0.13; 0.45) 0.21 (-0.13; 0.45) 0.21 (-0.13; 0.45) 0.21 (-0.13; 0.45) 0.71 (-0.11; 0.45) 1.18 (-0.95; 1.42) 0.06 (-0.21; 0.33) 0.06 (-0.21; 0.33) 0.06 (-0.13; 0.13) 0.07 (-0.13; 0.13) 0.07 (-0.13; 0.14) 0.07 (-0.14; 0.34) 0.07 (-0.14; 0.34) 0.07 (-0.14; 0.34) 0.07 (-0.14; 0.04)
(C)	Source Paile P. 1995 Niemela S. 1996 (Coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CagA(+)) Chimienti G. 2003 (CagA(-)) Sung KC. 2005 Osava H. 2005 Osava H. 2005 Longo-Menza B. 2007 Yura A. 2007 Kogawa T. 2008 Kucukazman M. 2009 Jia EZ. 2009 Akasy H. 2009 (Preeclampsia) Akasy H. 2009 (Preeclampsia)	SMD (95% CI) OD1 [-018; 0.21] 	(D) Source Niemala S. 1998 (control) Niemala S. 1998 (coronary heart disea Minami J. 2002 Chrimienti G. 2003 (CagA(+)) Chrimienti G. 2003 (CagA(+)) Sung KC. 2005 Sajor Y. 2005 Caswa H. 2005 Longo-Mbenza B. 2007 Yura A. 2007 Kucukuzman M. 2009 Jia EZ. 2009 Akasy H. 2009 (Preedampsia) Akasy H. 2009 (Normal pregnancy) Satch H. 2010 Haron B. 2011 (CapA(a))	SMD (85% CI) 1.83 [1 20; 2.05] 1.91 (10.78; 1.80] -1.80 [2.05; 1.56] < 0.21 [0.25; 0.46] 0.21 [0.13; 0.55] 0.06 [0.04; 0.07] 0.06 [0.04; 0.07] 0.06 [0.01; 0.15] -1.27 [1.53; 0.50] < 0.06 [0.21; 0.33] 0.06 [0.21; 0.33] 0.06 [0.21; 0.33] 0.00 [0.13; 0.13] 0.04 [0.14; 0.34] 0.04 [0.14; 0.34] 0.05 [0.01; 0.10] 0.05 [0.01] 0.05] 0.05 [0.05] 0.05 [0.05]
(C)	Source Patel P 1995 Nikimelia S. 1996 (Coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CapA(+)) Chimienti G. 2003 (CapA(-)) Sung KC. 2005 Longo-Mberza B. 2007 Yura A. 2007 Kogawa T. 2008 Koguwa H. 2005 Longo-Mberza B. 2007 Yura A. 2007 Kogawa T. 2008 Kucukazman M. 2009 Jia EZ. 2009 Akaoy H. 2006 (Normal pregnancy) Huang B. 2011 (CapA(+)) Huang B. 2011 (CapA(-))	SMD (95% CI) OO1 (-0.18, 0.21) 	(D) Source Nimenia S. 1996 (control)) Nimenia S. 1996 (Coronary heart disea Minarri J. 2002 Chrimieri G. 2003 (CapA(+)) Chrimieri G. 2003 (CapA(+)) Chrimieri G. 2003 (CapA(+)) Sung KC. 2005 Saligi Y. 2007 Yura A. 2007	SMD (95% CI) 1.63 (1 20; 2.05) =9) 1.19 (0.78; 1.60) -1.80 (2.05; -1.56) < 0.01 (0.25; 0.64) -2.21 (0.13; 0.85) 0.06 (0.04; 0.07) 0.08 (0.01; 0.15) -1.22 (1.63; -0.90) < 0.71 (-0.11; 0.45) 1.18 (0.95; 1.42) 0.06 (0.21; 0.33) 0.07 (-0.23; 1.16) -0.16 (0.00; 0.28) -0.16 (0.00; 0.01) -0.16 (0.00; 0.28) -0.16 (0.00; 0.01; 0.00) -0.16 (0.00; 0.01) -0.16 (0.00; 0.01) -0.
(C)	Source Patel P. 1995 Niemela S. 1996 (Coronary heart disease) Minami J. 2002 Chrinienti G. 2003 (CagA(+)) Chrinienti G. 2003 (CagA(-)) Sung KC: 2005 Sagio Y. 2005 Caswał H. 2005 Caswał H. 2005 Caswał H. 2005 Kucakazman M. 2009 Jia EZ. 2009 Aksoy H. 2009 (Preachampsia) Aksoy H. 2009 (Preachampsia) Aksoy H. 2009 (Normal pregnancy) Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(-)) Matsummura K. 2011	SMD (95% CI) OD [018; 021] OD6[-029; 0.44] OD6[-039; 023] OD6[-043; 032] OD6[-043; 032] OD7[-018; 022] OD7[-018; 022] OD7[-018; 022] OD7[-018; 023] OD7[-018; 023] OD7[-018; 023] OD7[-018; 024] OD7[-018; 024]	(D) Source Niemela S. 1996 (control) Niemela S. 1996 (Coronary heard disea Minand J. 2002 Chrimient G. 2003 (CapA(+)) Chrimient G. 2003 (CapA(-)) Sung KC. 2005 Sajor Y. 2005 Sajor Y. 2005 Charave H. 2006 Charave H. 2007 Charave H. 2009 Charave H. 2	SMD (65% C1) 1.63 (1 20, 2.05) 1.19 (10.78; 1.60) -1.30 (2.05; -1.56) < 0.11 (0.25; 0.46) 0.21 (0.13; 0.55) 0.06 (0.04; 0.07) 0.06 (0.01; 0.15) -1.27 (1.43; -0.09) < 0.17 (0.11; 0.45) 1.18 (0.95; 1.42) 0.06 (0.21; 0.03) 0.06 (0.21; 0.04) 0.05 (0.06; 0.09) 0.12 (0.06; 0.04)
(C)	Source Paile P. 1995 Niemeia S. 1996 (Coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CagA(+)) Chimienti G. 2003 (CagA(-)) Sung KC. 2005 Sasio Y. 2005 Dawa H. 2005 Longo-Mbenza B. 2007 Yura A. 2007 Kogawa T. 2008 Kucukazman M. 2009 Jia EZ. 2009 Aksoy H. 2009 (Preeclampsia) Aksoy H. 2009 (Preeclampsia) Aksoy H. 2009 (Preeclampsia) Masummura K. 2011 Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(-)) Mastummura K. 2011 Kim HL. 2011	SMD (95% CI) OD1 [-018; 0.21] 	(D) Source Niemala S. 1998 (control) Niemala S. 1998 (coronary heart disea Minami J. 2002 Chrimienti G. 2003 (CagA(+)) Chrimienti G. 2003 (CagA(+)) Sung KC. 2005 Sajo Y. 2005 Sajo Y. 2005 Cawa H. 2005 Longo-Mbenza B. 2007 Yura A. 2007 Kucukuzman M. 2009 Jia EZ. 2009 Akasoy H. 2009 (Preedampsia) Akasoy H. 2009 (Normal pregnancy) Sakoh H. 2010 Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(+))	SMD (85% C1) 1.63 [1 20; 2.05] 1.91 (10.78; 1.60] -1.80 [2.05; 1.64] 0.05 [0.08; 0.07] 0.06 [0.04; 0.07] 0.06 [0.04; 0.07] 0.06 [0.04; 0.07] 0.07 [0.01; 0.45] -1.27 [1.63, -0.50] < 0.06 [0.21; 0.45] 0.06 [0.21; 0.45] 0.07 [0.22] 0.16 [0.60; 0.28] 0.12 [0.10; 0.34] 0.12 [0.10; 0.24] 0.13 [0.05; 0.22]
(C)	Source Patel P. 1995 Numenia S. 1996 (Coronary heart disease) Minamia J. 2002 Chmianti G. 2003 (CapA(+)) Chminenti G. 2003 (CapA(-)) Sung KC. 2005 Saijo Y. 2005 Oasaw H. 2005 Longo-Mherza B. 2007 Yura A. 2007 Kouskazman M. 2009 Jaie E. 2009 Akaoy H. 2009 (Procelampsia) Akaoy H. 2009 (Normal regnancy) Huang B. 2011 (CapA(+)) Huang B. 2011 (CapA(+)) Maturmuruk K. 2011 Kim HL. 2011 Said Ar-Braweir. 2013	SMD (95% CI) OO1 (-0.18, 0.21) 	(D) Source Niemela S. 1996 (Coronary heart disea Minami J. 2002 Chimienti G. 2003 (CapA(+)) Chimienti G. 2003 (CapA(+)) Chimienti G. 2003 (CapA(+)) Sung KC. 2005 Saijo Y. 2005 Saijo Y. 2005 Casava H. 2005 Corona H. 2005 Corona H. 2007 Yura A. 2007 Yura A	SMD (95% C) 1.63 (1 20; 2.05) 1.19 (1.078; 1.60) 1.19 (1.078; 1.60) 1.19 (1.078; 1.60) 1.19 (1.025; 0.46) 0.06 [0.04; 0.07] 0.06 [0.04; 0.07] 0.06 [0.01; 0.15] 1.17 (1.15; 0.45] 0.07 [0.13; 0.45] 0.07 [0.13; 0.41] 0.06 [0.21; 0.33] 0.00 [0.13; 0.13] 0.04 [0.21; 0.33] 0.04 [0.21; 0.33] 0.04 [0.21; 0.33] 0.04 [0.21; 0.33] 0.04 [0.21; 0.33] 0.04 [0.21; 0.33] 0.04 [0.21; 0.34] 0.05 [0.01] 0.16 [0.60; 0.28] 0.12 [0.00; 0.41] 0.12 [0.00; 0.41] 0.12 [0.00; 0.41] 0.14 [0.05; 0.22] 0.14 [0.05; 0.22] 0.15 [0.05; 0.25] 0.15 [0.05; 0.25] 0.15 [0.05; 0.25] 0.15 [0.05; 0.25] 0.15 [0.05; 0.25] 0.15 [0.05; 0.25] 0.
(C)	Source Patel P. 1995 Numenia S. 1996 (Coronary heart disease) Miamari J. 2002 Chmienti G. 2003 (CagA(+)) Chmienti G. 2003 (CagA(-)) Sang KC. 2005 Salgi Y. 2005 Orawa H. 2005 Longo-Mencra B. 2007 Yura A. 2007 Kucakazman M. 2009 Jia E. 2009 Akacy H. 2009 (Preachampsia) Akacy H. 2009 (Preachampsia) Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(-1)) Kisumura K. 2011 Kim HL. 2011 Saud Al-Fawaeir. 2013 Gerg R. 2013 Gerg R. 2013	SMD (95% CI) OD [0.18; 0.21]	(D) Source Niemela S. 1996 (Corton) Niemela S. 1996 (Coronary heard disea Minand J. 2002 Chrimient G. 2003 (CapA(+)) Chrimient G. 2003 (CapA(-)) Sung KC. 2005 Sajo Y. 2005 Sajo Y. 2005 Charave H. 2005 Sajo Y. 2009 Asay H. 2009 (Preeclampsia) Asay H. 2009 (Preeclampsia) Asay H. 2009 (Preeclampsia) Asay H. 2009 (Preeclampsia) Asay H. 2009 (Preeclampsia) Matsummura K. 2011 Kim HL. 2011 Kim HL. 2011	SMD (6% C) 1.63 (1 20, 2.05) 1.91 (19 (7.8°, 1.60) -1.30 (2.205, 1.56) < 0.21 (0.13, 0.55) 0.21 (0.13, 0.55) 0.06 (0.04°, 0.07) 0.06 (0.01°, 0.15) -1.27 (1.43, -0.09) < 0.17 (-0.11°, 0.45) 1.18 (0.95°, 1.42) 0.06 (0.21°, 0.03) 0.06 (0.21°, 0.03) 0.06 (0.21°, 0.03) 0.06 (0.21°, 0.03) 0.06 (0.21°, 0.03) 0.06 (0.21°, 0.03) 0.05 (0.01°, 0.10) 0.05 (0.01°, 0.10) 0.05 (0.02°, 0.04) 0.13 (-0.05, 0.32) 0.48 (0.22°, 0.74] 0.48 (0.20°, 0.74]
(C)	Source Patel P 1995 Niemela S. 1996 (coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CagA(+)) Chimienti G. 2003 (CagA(+)) Chimienti G. 2003 (CagA(-)) Sanja Y. 2005 Casava H. 2005 Longo-Monera B. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Kuckazman M. 2009 Jia E.Z. 2009 Jia E.Z. 2009 Jia E.Z. 2009 Jia E.Z. 2009 Jia E.Z. 2009 Jia E.Z. 2019 Jia E.Z. 2011 Matsummura K. 2011 Kim HL. 2011 Said A.Fawaei; 2013 Camig R. 2013 (male) Yumano, B. 2011 (formale)	SMD (95% CI) OD1 [-018; 0.21] 	(D) Source Niemala S. 1998 (control) Niemala S. 1998 (coronary heart disea Minamai J. 2002 Chrimienti G. 2003 (CagA(+)) Chrimienti G. 2003 (CagA(+)) Chrimienti G. 2003 (CagA(+)) Sung KC. 2005 Saljo Y. 2005 Saljo Y. 2005 Cawaw H. 2005 Long-Mbenza B. 2007 Yura A. 2007 Kucukuzman M. 2009 Jia EZ. 2009 Akasy H. 2009 (Preedampsia) Akasy H. 2009 (Normal pregnancy) Saloh H. 2010 Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(+)) Huang B. 2011 Kim HL. 2011 Kim HL. 2011 Kim HL. 2011	SMD (85% C1) 1.63 [1 20; 2.05] 1.91 (10.78; 1.60] 1.92 (10.78; 1.60] 1.92 (10.78; 1.60] 1.92 (10.78; 1.60] 0.01 [0.25; 0.46] 0.05 (10.94; 0.07] 0.06 [0.21; 0.05] 1.16 [0.95; 1.42] 0.06 [0.21; 0.45] 1.18 [0.95; 1.42] 0.06 [0.21; 0.45] 0.06 [0.22; 0.74] 0.06 [0.22; 0.25] 0.05 [0.25] 0.05 [0.05] 0.05 [0.05
(C)	Source Patel P. 1995 Nikmeila S. 1996 (Coronary heart disease) Minana J. 2002 Chmiandi G. 2003 (CagA(+)) Chmindi G. 2003 (CagA(-)) Sung KC. 2005 Saigo Y. 2005 Oasaw H. 2005 Longo-Mbenza B. 2007 Yura A. 2007 Kouskazman M. 2009 Jaile E. 2009 Akasy H. 2005 (Orgode (Preclampsia) Akasy H. 2009 (Procelampsia) Akasy H. 2009 (Procelampsia) Akasy H. 2010 (CagA(+)) Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(+)) Mass M. 2011 Said A.F.Fawaeir. 2013 Garig R. 2013 Yamamook R. 2013 (female) Yatamamok T. 2013 (female) Yatamamok T. 2013 (female)	SMD (95% CI) OOT [0-18, 0-21] 	(D) Source Nimenia S. 1996 (Coronary heart disea Minami J. 2003 (CapA(+)) Chimienti G. 2003 (CapA(+)) Chimienti G. 2003 (CapA(+)) Chimienti G. 2003 (CapA(+)) Sung KC. 2005 Saijo Y. 2005 Saijo Y. 2005 Saijo Y. 2005 Saijo Y. 2005 Marca B. 2007 Yura A. 2007 Yura A. 2007 Kucikazman M. 2009 (Nemal programcy) Jia EZ. 2009 Akasy H. 2009 (Nemal programcy) Satoh H. 2010 Satoh H. 2011 Marca B. 2011 (CapA(+)) Huang B. 2011 (CapA(+)) Huang B. 2011 (CapA(+)) Huang B. 2011 (CapA(+)) Huang B. 2011 (CapA(+)) Matummura K. 2011 Sata Al-Forware. 2013 Gerig R. 2013 Vateriamenti J. 2014 (Nondiabetic) Vateriamenti J. 2014 (Nondiabetic)	SMD (95% C) 1.63 (1 20; 2.05) 1.19 (1.07; 1.60) 1.19 (1.07; 1.50) 1.19 (1.07; 1.50) 1.19 (1.05; 1.56) < 0.01 (1.02; 0.46) 0.21 (0.13; 0.55) 0.06 (0.04; 0.07) 0.06 (0.01; 0.15) 1.17 (1.15; 0.45) 0.07 (1.01; 0.45) 0.07 (0.13; 0.13) 0.06 (0.21; 0.33) 0.00 (0.13; 0.13) 0.00 (0.14; 0.33) 0.00 (0.14; 0.34) 0.05 (1.04; 0.34) 0.11 (0.05; 0.32] 0.48 (0.22; 0.74] 0.05 (0.24; 0.25) 0.57 (0.25; 0.25; 0.25) 0.57 (0.25; 0.25; 0.25; 0.25) 0.57 (0.25; 0
(C)	Source Patel P. 1995 Patel P. 1995 Niemela S. 1996 (Cortoral) Niemela S. 1996 (Cortoraly heart disease) Mamari J. 2002 Chmienti G. 2003 (CagA(+)) Chmienti G. 2003 (CagA(-)) Sung KC. 2005 Saloy Y. 2005 Chargenti G. 2003 (CagA(-)) Sung KC. 2005 Diago M. 2005 Casava H. 2005 Chargenti A. 2007 Kugakar T. 2008 Kugakar T. 2008 Kucukazman M. 2009 Jai E. 2009 Aksoy H. 2009 (Preschampsia) Aksoy H. 2009 (Preschampsia) Aksoy H. 2009 (Preschampsia) Matsummura K. 2011 Kim HL. 2011 Sand A.Fawaeir. 2013 Geig R. 2013 Yamamoto R. 2013 (male) Yamamoto R. 2013 (male) Variamament J. 2014 (Mostabetic) Variatemment-J. 2014 (Mostabetic)	SMD (95% CI) OD [0 18, 0 21] OD [0 18, 0 21] OD [0 18, 0 23] OD [0 14, 0 05] < OD [0 14, 0 05] < OL [0 14, 0 05] < OL [0 17, 0 18, 0 25] OL [0 12, 0 16] OL [0 03, 0 16] OL [0 14, 0 12] OL [0 04] OL [0 14, 0 12] OL [0 05, 1 86] OL [0 05, 0 18] OL [0 05, 0 05] OL [0 05,	(D) Source Niemela S. 1998 (Coronary heard disea Minani J. 2002 Chrimienti G. 2003 (CapA(+)) Chrimienti G. 2003 (CapA(-)) Sung KC. 2005 Sajo Y. 2005 Sajo Y. 2005 Sajo Y. 2005 Chara B. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2009 Alasy H. 2009 (Preeclampsia) Alasy H. 2009 (Preeclampsia) Alasy H. 2009 (Preeclampsia) Alasy H. 2009 (Preeclampsia) Matsummura K. 2011 Kim H. 2011 Kim H. 2011 Said AF-Amaeter. 2013 Greig R. 2013 Vafaeimanesh J. 2014 (Nondabetic) Uz 2014	SMD (95% CI) 1.63 [1.20, 2.05] 1.91 [1.91 (7.8°, 1.60] 1.191 (7.8°, 1.60] 1.191 (7.8°, 1.60] 0.21 [0.13, 0.55] 0.21 [0.13, 0.55] 0.21 [0.13, 0.55] 0.21 [0.13, 0.55] 0.21 [0.11, 0.45] 1.181 (0.5°, 1.42] 0.06 [0.21; 0.03] 0.06 [0.21; 0.03] 0.06 [0.21; 0.03] 0.07 [0.01; 0.10] 0.47 [0.23, 1.16] 0.47 [0.23, 1.16] 0.112 [0.00] 0.47 [0.23, 1.16] 0.47 [0.23, 1.16] 0.48 [0.22; 0.74] 0.48 [0.22; 0.74] 0.55 [0.24, 0.23] 0.57 [0.44] 0.57 [0.57]
(C)	Source Patel P. 1995 Niemela S. 1996 (Coronary heart disease) Minami J. 2002 Chrimenti G. 2003 (CagA(+)) Chrimenti G. 2003 (CagA(-)) Sung KC. 2005 Saija Y. 2005 Casava H. 2005 Longo-Mhorez B. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Kucukazman M. 2009 Jia EZ. 2009 Akasy H. 2009 (Preaclampsia) Akasy H. 2009 (Preaclampsia) Akasy H. 2009 (Preaclampsia) Akasy H. 2009 (Preaclampsia) Akasy H. 2009 (Preaclampsia) Masummar K. 2011 Kim HL. 2011 Said A.Fawaeir. 2013 Gerig R. 2013 Yamamoto R. 2013 (male) Yamamoto R. 2014 (Mondaberio) Vateimanesh J. 2014 (Mondaberio) Vateimanesh J. 2014 (Mondaberio)	SMD (95% CI) OD1 [-018; 0.21] 	(D) Source Nimenia S. 1996 (control)) Nimenia S. 1996 (control) Nimenia S. 1996 (control) Nimenia S. 2003 (Cap4(+)) Chrimetia G. 2003 (Cap4(+)) Chrimetia G. 2003 (Cap4(+)) Sung KC. 2005 Saligi Y. 2	SMD (85% CI) 1.83 [1 20; 2.05] a) 1.19 [0.78; 1.80] -1.80 [2.05; 1.68] 0.11 [0.25; 0.46] 0.21 [0.13; 0.55] 0.06 [0.04; 0.07] 0.06 [0.04; 0.07] 0.06 [0.04; 0.07] 0.06 [0.04; 0.07] 0.06 [0.04; 0.05] 0.07 [0.01; 0.45] 1.18 [0.95; 1.42] 0.06 [0.21; 0.33] 0.00 [0.01; 0.13] 0.040 [1.14; 0.34] 0.05 [0.02; 0.01] 0.18 [0.60; 0.22] 0.14 [0.40; 0.24] 0.14 [0.06; 0.22] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.22; 0.74] 0.05 [0.24; 0.23] 0.05 [0.24; 0.23] 0.05 [0.24; 0.25] 0.05 [0.24; 0.25]
(C)	Source Patel P. 1995 Numenia S. 1996 (Coronary heart disease) Minama J. 2002 Chmiendi G. 2003 (CagA(+)) Chmiendi G. 2003 (CagA(-)) Sung KC. 2005 Saijo Y. 2005 Osaya H. 2005 Longo-Mbenza B. 2007 Yura A. 2007 Kouckazman M. 2009 Jaie E. 2009 Akaoy H. 2009 (Preclampeia) Akaoy H. 2009 (Normal pregnancy) Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(+)) Masay H. 2015 Kim HL. 2011 Saad Al-Fawaeir. 2013 Geing R. 2013 Yamamok R. 2013 (female) Yafaeimanesh J. 2014 (Mondiabetic) Vafaeimanesh J. 2014 (Dabetic) Lud Cay14	SMD (95% C1) OOT [0-18: 0.21] 	(D) Source Nimenia S. 1996 (Coronary heard disea Minanii J. 2002 Chimienia G. 2003 (CapA(+)) Chimienia G. 2003 (CapA(+)) Chimienia G. 2003 (CapA(+)) Sung KC. 2005 Saigo Y. 2005 Saigo Y. 2005 Saigo Y. 2005 Saigo Y. 2005 Jai EZ. 2009 Akasoy H. 2009 (Preeclampsia) Akasoy H. 2009 (Preeclampsia) Kiuciuzama M. 2009 Matsurburg X. 2014 Huang B. 2011 (CapA(+)) Huang B. 2014 (CapA(+))	SMD (6% C) 1.63 (1 20, 2.05) 1.19 (1 0.78; 1.60) 1.19 (1 0.78; 1.60) 1.19 (1 0.78; 1.60) 0.11 (0 25; 0.46) 0.21 (-0.13; 0.55) 0.21 (-0.13; 0.55) 0.21 (-0.13; 0.55) 0.21 (-0.13; 0.55) 0.27 (-0.13; 0.00) < 0.71 (-0.11; 0.45) 1.18 (0.95; 1.42) 0.06 (-0.21; 0.33) 0.06 (-0.21; 0.33) 0.05 (-0.01; 0.10) 0.05 (-0.01; 0.10) 0.05 (-0.01; 0.10) 0.05 (-0.01; 0.02) 0.05 (-0.01; 0.02) 0.05 (-0.02; 0.44) 0.13 (-0.05; 0.32) 0.05 (-0.22; 0.74) 0.05 (-0.23) 0.05 (-0.23) 0.05 (-0.23) 0.05 (-0.24; 0.22) 0.05 (-0.24; 0.22) 0.05 (-0.24; 0.22) 0.05 (-0.24; 0.23) 0.05 (-0.24; 0.25) 0.05 (-0.2
(C)	Source Patel P. 1995 Numenia S. 1996 (Coronary heart disease) Miamari J. 2002 Chmienti G. 2003 (CagA(+)) Sung KC. 2005 Sang KC. 2005 Sagio Y. 2005 Oragen A. 2007 Yura A. 2007 Kogawa T. 2008 Kucukazman M. 2009 Jaie Z. 2009 Aksoy H. 2009 (Preachampsia) Aksoy H. 2009 (Preachampsia) Aksoy H. 2009 (Preachampsia) Maturura K. 2011 Kim HL. 2011 Saud A.Fraweir. 2013 Gerg R. 2013 Yamamoto R. 2013 (male) Variammenta J. 2014 (Nordiabetic) Variamenseh J. 2014 (Nordiabetic) Variamenseh J. 2014 (Sontiabetic) Variamenseh J. 2014 (Sontiabetic)	SMD (95% CI) OD [0 18, 0 21] OD [0 18, 0 21] OD [0 18, 0 23] OD [0 14, 0 05] < OD [0 03, 0 16] OD [0 03, 0 16] OD [0 04, 0 23] < OD [0 04, 0 24] < OD [0 04, 0 12] < OD [0 05, 0 04] < OD [0 05, 0 05] < OD	(D) Source Niemela S. 1998 (Coronary heard disea Minani J. 2002 Chrimienti G. 2003 (CapA(+)) Chrimienti G. 2003 (CapA(-)) Sung KC. 2005 Sajo Y. 2005 Sajo Y. 2005 Sajo Y. 2005 Charge-Miserza B. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2009 Alasy H. 2009 (Preectampsia) Alasy H. 2009 (Preectampsia) Alasy H. 2009 (Preectampsia) Alasy H. 2009 (Preectampsia) Alasy H. 2009 (Preectampsia) Matsummura K. 2011 Kim H2011 Kim H2011 Kim H2013 Gring R. 2013 Vafaeimanesh J. 2014 (Nondabetic) U. C. 2014 Kimpoza A. 2014 Chen LW. 2015 Chen TP. 2015 (male)	SMD (95% C1) 1.63 [1.20, 2.05] 1.91 [1.91 (7.8°, 1.60] 1.191 (7.8°, 1.60] 1.191 (7.8°, 1.60] 0.21 [0.13, 0.55] 0.21 [0.13, 0.55] 0.06 [0.04; 0.07] 0.06 [0.04; 0.07] 0.07 [0.01; 0.15] 1.18 [0.95; 1.42] 0.06 [0.21; 0.03] 0.06 [0.21; 0.03] 0.06 [0.21; 0.03] 0.07 [0.01; 0.10] 0.07 [0.01; 0.10] 0.047 [0.23; 1.16] 0.05 [0.02; 0.02] 0.12 [0.01; 0.04] 0.12 [0.01; 0.04] 0.12 [0.01; 0.04] 0.13 [0.05; 0.22] 0.14 [0.20; 0.74] 0.05 [0.24; 0.23] 0.05 [0.24; 0.23] 0.05 [0.24; 0.23] 0.05 [0.24; 0.23] 0.05 [0.24; 0.25] 0.05 [0.24; 0.27] 0.14 [0.00; 0.28] 0.17 [0.07; 0.27]
(C)	Source Patel P. 1995 Patel P. 1995 Nimmela S. 1996 (Coronary heart disease) Minamia J. 2002 Chimienti G. 2003 (CapA(+)) Chimienti G. 2003 (CapA(-)) Sung KC. 2005 Saipa' Y. 2005 Calona M. 2005 Longo-Mberza B. 2007 Yura A. 2007 Yura A. 2007 Kozakarnan M. 2009 Jai EZ. 2009 Akaoy H. 2006 (Preschampsia) Akaoy H. 2006 (Preschampsia) Nasoy H. 2006 (Preschampsia) Masury M. 2009 (Preschampsia) Masurmura K. 2011 Kim H. 2011 Capa(-)) Mang B. 2011 (CapA(+)) Maug B. 2011 (CapA(-)) Mang A. Arawaeir. 2013 Garig R. 2013 Yamamoto R. 2013 (Ismale) Yamamoto R. 2013 (Ismale) Yamamoto R. 2013 (Ismale) Yateimanesh. J. 2014 (Diabetici) Lui C. 2014 Karpouza A. 2014 Chen IV. 2015 Chen IV. 2015	SMD (95% CI) OO1 (-0.18, 0.21) 	(D) Source Nimenia S. 1996 (control)) Nimenia S. 1996 (control) Nimenia S. 1996 (control) Chrimeria G. 2003 (Cap4(+)) Chrimeria G. 2003 (Cap4(+)) Chrimeria G. 2003 (Cap4(+)) Sung KC. 2005 Saligi Y. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Kucukazman M. 2009 Jia E. 2. 2009 Aksoy H. 2009 (Preeclampsia) Aksoy	SMD (85% C1) 1.63 [1 20; 2.05] 1.9 [1.9 [0.78; 1.60] 1.8 [2.107; 1.60] 1.8 [2.107; 1.60] 1.8 [2.107; 1.60] 0.06 [0.01; 0.15] 1.7 [0.11; 0.45] 1.7 [0.11; 0.45] 0.06 [0.21; 0.45] 0.05 [0.01; 0.10] 0.15 [0.60; 0.28] 0.15 [0.20; 0.21] 0.45 [0.20; 0.71] 0.45 [0.20; 0.25] 0.45 [0.24; 0.28] 1.16 [1.55, 0.79] < 1.16 [1.55, 0.79] < 0.45 [0.24; 0.28] 0.45 [0.24;
(C)	Source Patel P. 1995 Patel P. 1995 Nikmeila S. 1996 (Cortoral) Nikmeila S. 1996 (Cortoraly heart disease) Minarul J. 2002 Chmiendi G. 2003 (CagA(+)) Chmiendi G. 2003 (CagA(-)) Sung KC. 2005 Saijo Y. 2005 Osaya H. 2005 Longo-Mhenza B. 2007 Yura A. 2007 Kogawa T. 2008 Kucukazman M. 2009 Jaie E. 2009 Akaoy H. 2009 (Procelampsia) Akaoy H. 2009 (Procelampsia) Akaoy H. 2009 (Normal pregnancy) Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(+)) Matummura K. 2011 Saad Al-Fawaeir. 2013 Geing R. 2013 Yamamoko R. 2013 (male) Yamamoko R. 2013 (male) Yafaeimanesh J. 2014 (Nondiabetic) Vafaeimanesh J. 2014 (Dabetic) Vafaeimanesh J. 2014 (Dabetic) Luc 2:014 Kampouza A. 2014 Chen I.W. 2015 Chen I.W. 2015 (cimale) Chen IP. 2015 (male)	SMD (95% CI) OOT [0-18: 0.21] 0.06 [-0.29: 0.44] 0.06 [-0.39: 0.22] 0.06 [-0.43: 0.22] 0.07 [-0.18: 0.22] 0.07 [-0.12: 0.81] 0.06 [-0.06: 0.10] 0.06 [-0.06: 0.10] 0.06 [-0.06: 0.10] 0.06 [-0.43: 0.87] 0.06 [-0.43: 0.87] 0.06 [-0.43: 0.87] 0.06 [-0.43: 0.87] 0.07 [-0.14: 0.12] 0.07 [-0.17: 0.28] 0.07 [-0.23: 0.68] 0.21 [-0.52: 0.95] 0.03 [-0.09; 0.42] 0.23 [-0.03: 0.48] 0.23 [-0.03: 0.48] 0.23 [-0.03: 0.48] 0.23 [-0.03: 0.48] 0.23 [-0.03: 0.48] 0.23 [-0.03: 0.48] 0.23 [-0.03: 0.48] 0.05 [-0.05: 0.15] 0.06 [-0.38] 0.05 [-0.05: 0.15] 0.06 [-0.38] 0.05 [-0.05] 0.05 [-0.05] 0.	(D) Source Nimenia S. 1996 (Coronary heard disea Minanii J. 2002 Chimienia G. 2003 (CapA(+)) Chimienia G. 2003 (CapA(+)) Chimienia G. 2003 (CapA(+)) Sung KC. 2005 Saigo Y. 2005 Saigo Y. 2005 Jaige Z. 2005 Jaige Z. 2009 Akasy H. 2009 (Preeclampsia) Akasy H. 2009 (Preeclampsia) Kini H. 2011 Saad Al-Farwaeir. 2013 Gerig R. 2013 Vafaeimaneh J. 2014 (Nordiabetic) Vafaeimaneh J. 2015 (Genale) Chen TP. 2015 (female) Sun Y. 2016	SMD (95% C) 1.63 (1 20, 2.05) 1.91 (19 (7.8°, 1.60) -1.30 (2.05, 1.56) < 0.21 (-0.13, 0.55) 0.21 (-0.13, 0.55) 0.21 (-0.13, 0.55) -1.27 (1.43, -0.09) < 0.77 (-0.11; 0.45) 0.77 (-0.11; 0.45) 0.75 (-0.02) 0.75 (-0.02; 0.74) 0.75 (-0.22; 0.74) 0.75 (-0.22; 0.74) 0.75 (-0.22; 0.74) 0.77 (-0.7; 0.27) 0.77 (-0.4; 0.22) 0.77 (-0.4; 0.29) 0.77 (-0.4; 0.29] 0.77 (-0.4
(C)	Source Patel P. 1995 Numenia S. 1996 (Coronary heart disease) Miamari J. 2002 Chmienti G. 2003 (CagA(+)) Sung KC. 2005 Sang KC. 2005 Sagio Y. 2005 Oramon G. 2003 (CagA(-)) Sung KC. 2005 Osaya H. 2005 Oramon G. 2003 (CagA(-)) Kogawa T. 2008 Kucakazman M. 2009 Jai E. 2009 Aksoy H. 2009 (Preachampia) Aksoy H. 2009 (Preachampia) Aksoy H. 2009 (Preachampia) Matumura K. 2011 Kim HL. 2011 Saud Al-Fawaie: 2013 Geing R. 2013 Yamamok R. 2013 (male) Variammaneh J. 2014 (Nordiabetic) Variaminena J. 2014 (Nordiabetic) Variaminena J. 2014 (Nordiabetic) Variaminena J. 2014 (Nordiabetic) Luc 2:014 Karpuza A. 2014 Chen IV. 2015 Chen IV. 2015 Chen TP. 2015 (temale) Chen TP. 2015 (temale) Chen TP. 2015 (temale)	SMD (95% CI) OD [0 18, 0 21] OD [0 18, 0 21] OD [0 18, 0 23] OD [0 14, 0 051] < OD [0 14, 0 051] < OD [0 14, 0 051] < OD [0 14, 0 05] < OD [0 03, 0 16] OD [0 04, 0 23] < OD [0 04, 0 12] < OD [0 05, 0 04]	(D) Source Niemela S. 1998 (Coronary heard disea Minami J. 2002 Chrimienti G. 2003 (CapA(+)) Chrimienti G. 2003 (CapA(-)) Sung KC. 2005 Sajo Y. 2005 Sajo Y. 2005 Chara B. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Alsoy H. 2009 (Preectampsia) Alsoy H. 2009 (Preectampsia) Alsoy H. 2009 (Preectampsia) Alsoy H. 2009 (Preectampsia) Masummura K. 2011 Kim HL. 2011 Kim HL. 2011 Said A.Fameeli, 2013 Gring R. 2013 Vafaeimanesh J. 2014 (Nondabetic) U. Vafaeimanesh J. 2014 (Nondabetic) U. Vafaeimanesh J. 2014 (Nondabetic) U. Capation J. 2015 Chen TP. 2015 (maile) Sun Y. 2016 Sun Y. 2016 Chen TP. 2015 (maile) Sun Y. 2016 Chen TP. 2015 (maile)	SMD (95% C1) 1.63 [1.20, 2.05] 1.91 (1.91 (7.81, 1.60] 1.19 (1.781, 1.60] 1.19 (1.781, 1.60] 0.21 (0.13, 0.55] 0.21 (0.13, 0.55] 0.21 (0.13, 0.55] 0.06 (0.04), 0.07] 0.06 (0.21, 0.03] 0.07 (0.01, 0.15] 1.18 (0.95, 1.42] 0.06 (0.21, 0.03] 0.07 (0.21, 0.03] 0.07 (0.23, 1.16] 0.04 (1.23, 0.04] 0.04 (1.23, 0.16] 0.04 (1.24, 0.23] 0.05 (0.03) 0.12 (0.10, 0.34] 0.13 (0.05, 0.22] 0.12 (0.10, 0.34] 0.13 (0.05, 0.22] 0.13 (0.05, 0.22] 0.14 (0.20, 0.70] 0.48 (0.22, 0.74] 0.05 (0.24, 0.23] 0.05 (0.24, 0.23] 0.05 (0.24, 0.23] 0.05 (0.24, 0.23] 0.14 (0.00, 0.28] 0.14 (0.00, 0.08) 0.14 (0.00, 0.
(C)	Source Patel P. 1995 Nimenia S. 1996 (Coronary heart disease) Minamia J. 2002 Chimienti G. 2003 (CapA(+)) Chimienti G. 2003 (CapA(-)) Sung KC. 2005 Longo-Mberza B. 2007 Yura A. 2007 Kogawa T. 2008 Kozukazman M. 2009 Jiai EZ. 2009 Akaoy H. 2006 (Preschampsin) Akaoy H. 2006 (Preschampsin) Huang B. 2011 (CapA(+)) Huang B. 2011 (CapA(+)) Huang B. 2011 (CapA(+)) Yamamoto R. 2013 (male) Yamamoto R. 2013 (female) Yamamoto R. 2013 (female) Yateimanesh J. 2014 (Diabetic) Lui C. 2014 Karpouza A. 2014 Chen TP. 2015 (mine)	SMD (95% C1) O10 [0-18, 0-21] O.06 [0-29, 0.44] O.06 [0-39, 0-22] O-27 [0-18, 0-21] O-27 [0-18, 0-21] O-27 [0-18, 0-21] O-27 [0-12, 0-81] O-27 [0-12, 0-81] O-27 [0-12, 0-81] O-27 [0-22, 0-27] O-28 [0-22, 0-27] O-28 [0-22, 0-27] O-29 [0-22, 0-25] O-21 [0-21, 0-25] O-21 [0-21, 0-25] O-21 [0-21, 0-25] O-21 [0-21, 0-25]	(D) Source Nimenia S. 1996 (contor)) Nimenia S. 1996 (contor) Nimenia S. 1996 (contor) heart disea Minarri J. 2002 Chrimetii G. 2003 (Cap4(+)) Chrimetii G. 2003 (Cap4(+)) Chrimetii G. 2003 (Cap4(+)) Sung KC. 2005 Sajey Y. 2005 Osawa H. 2005 Congo. Mberza B. 2007 Yura A. 2007 Yura A. 2007 Yura A. 2007 Kucukazmam M. 2009 Jia E. 2. 2009 Akasy H. 2009 (Preeclampsia) Akasy H. 2019 (Preeclampsia) Akasy H. 201	SMD (89% CI) 1.83 [1 20; 2.06] 1.81 [1 20; 2.06] 1.81 [1 20; 2.06] 1.80 [2.05; 1.68] 0.11 [0.25; 0.46] 0.21 [0.13; 0.55] 0.06 [0.04; 0.07] 0.06 [0.04; 0.07] 0.06 [0.04; 0.07] 0.06 [0.04; 0.07] 0.06 [0.21; 0.15] 0.07 [0.11; 0.45] 1.18 [1 205; 1.42] 0.06 [0.21; 0.33] 0.00 [-0.13; 0.13] 0.04 [1.14; 0.43] 0.05 [0.01; 0.10] 0.16 [0.60; 0.28] 0.13 [0.05; 0.22] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.45 [0.20; 0.70] 0.46 [0.00; 0.28]
(C)	Source Patel P. 1995 Numenia S. 1996 (Coronary heart disease) Minama J. 2002 Chmiendi G. 2003 (CagA(+)) Chmiendi G. 2003 (CagA(-)) Sung KC. 2005 Saijo Y. 2005 Osaya H. 2005 Longo-Minerza B. 2007 Yura A. 2007 Kouckazman M. 2009 Jaie Z. 2009 Akasy H. 2009 (Preclampsia) Akasy H. 2009 (Normal pregnancy) Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(+)) Yamamok R. 2013 (Gmale) Yamamok R. 2013 (male) Yamamok R. 2013 (male) Yadaeimanesh J. 2014 (Dolabatici) Vafaeimanesh J. 2014 (Dalabatici) Vafaeimanesh J. 2014 (Dalabatici) Lu C. 2014 Kampouza A. 2014 Chen I.W. 2015 Chen T.P. 2015 (male) Sund Y. 2016 (Cantalia Syndrome X) Rasim Y. 2016 (Cantalia Syndrome X)	SMD (95% CI) OOT [0-18: 0.21] 0.06 [-0.29: 0.44] 0.06 [-0.39: 0.22] 0.06 [-0.49: 0.52] 0.07 [0-12: 0.61] 0.06 [-0.69: 0.10] 0.06 [-0.69: 0.10] 0.06 [-0.69: 0.10] 0.06 [-0.49: 0.25] 0.05 [-0.49: 0.79] 0.05 [-0.49: 0.79] 0.05 [-0.49: 0.79] 0.05 [-0.49: 0.79] 0.05 [-0.49: 0.79] 0.05 [-0.49: 0.79] 0.05 [-0.49: 0.79] 0.07 [-0.14: 0.12] 0.07 [-0.14: 0.12] 0.07 [-0.14: 0.12] 0.07 [-0.14: 0.12] 0.07 [-0.17: 0.28] 0.07 [-0.23] 0.06 [-0.30: 0.48] 0.23 [-0.03: 0.48] 0.05 [-0.05: 0.15] 0.06 [-0.38] 0.05 [-0.05] 0.05 [-0.	(D) Source Nimenia S. 1996 (Coronary heard disea Minami J. 2002 Chrimient G. 2003 (CapA(+)) Chrimin G. 2003 (CapA(+)) Chrimin G. 2003 (CapA(+)) Chrimin G. 2003 (CapA(+)) Chriment G. 2003 (CapA(-)) Sung KC. 2005 Salip Y. 2005 Salip Y. 2005 Charama M. 2005 Longo-Mberza B. 2007 Vura A. 2007 Kucidazmar M. 2009 Jai EZ. 2009 Alascy H. 2009 (Preeclampsia) Aksay H. 2019 (Dreate) Aksay H. 2019 (Cantola Syndrome X) Rammy H. 2016 (Cantola Syndrome X) Rammy H. 2016 (Cantola Syndrome X) Aksay H. 2016 (Cantola Syndrome X) Aksay H. 2016 (Cantola Cantola Syndrome X) Aksay H. 2016 (Cantola Cantola Syndrome X) Aksay H. 2016 (Cantola Cantola Syndrome X) Aksay H. 2014 (Cantola Cantola Syndrome	SMD (95% C) 1.63 (1 20, 2.05) 1.91 (19 (0.78; 1.60) -1.30 (2.05, 1.56) < 0.21 (-0.13; 0.55) 0.21 (-0.13; 0.55) 0.21 (-0.13; 0.55) 0.21 (-0.13; 0.55) 0.21 (-0.13; 0.55) 0.21 (-0.13; 0.55) 0.27 (-0.15; 0.50) < 0.77 (-0.11; 0.45) 0.77 (-0.11; 0.45) 0.75 (-0.02; 0.41) 0.75 (-0.02; 0.74) 0.75 (-0.02; 0.74) 0.77 (-
(C)	Source Patel P. 1995 Patel P. 1995 Nimenia S. 1996 (Cortonar) Niemela S. 1996 (Cortonary heart disease, Mamari J. 2002 Chrimerid G. 2003 (CagA(+)) Chrimerid G. 2003 (CagA(-)) Sung KC: 2005 Sang KC: 2005 CagaA(-)) Saljo Y. 2005 CagaA(-)) Chrimerid G. 2003 (CagA(-)) Sung KC: 2005 Charge M. 2005 CagaA(-)) Vura A. 2007 Yura A. 2007 Yura A. 2007 Kogawa T. 2008 Kucukazman M. 2009 Jia EZ. 2009 Akacy H. 2009 (Normal pregnancy) Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(+)) Huang B. 2011 (CagA(-1)) Matsummura K. 2011 Kim Hu. 2011 Sand A.Faweir, 2013 Gerig R. 2013 Yamamoto R. 2013 (female) Yamamoto R. 2013 (female) Yatelimmesh J. 2014 (Nordiabetic) Vatelimmesh J. 2014 (Caldiabetic) LV Lu C. 2014 Karpouz A. 2014 Karpouz A. 2015 Chen TP. 2015 (male) Chen TP. 2015 (male) Chen TP. 2015 (male) Sun Y. 2016 Raami Y. 2016 (Cardias Syndrome X)	SMD (95% C1) OD [0 18; 0 21] OD [0 18; 0 21] OD [0 18; 0 21] OD [0 14; 0 12] OD [0 15] OD [0 14] OD [0 15] OD [0 15]	(D) Source Niemela S. 1998 (Coronary heard disea Minami J. 2002 Chimienti G. 2003 (CapA(+)) Chimienti G. 2003 (CapA(-)) Sung KC. 2005 Sajo Y. 2005 Sajo Y. 2005 Charan H. 2005 Longo-Mherza B. 2007 Yura A. 2007 Yura A. 2007 Kucukazman M. 2009 Jia EZ. 2009 Akasy H. 2009 (Preeclampsia) Akasy H. 2009 (Preeclampsia) Akasy H. 2009 (Preeclampsia) Akasy H. 2009 (Preeclampsia) Akasy H. 2009 (Preeclampsia) Kucukazman M. 2009 Jia EZ. 2009 Matsumura K. 2011 Kim HL. 2011 Kim HL. 2011 Said AF. Amaetir. 2013 Gring R. 2013 Vafasimanesh J. 2014 (Notdiabetic) Luc. 2014 Kim Pouza A. 2014 Chen IV. 2015 Chen TP. 2015 (female) Sun Y. 2016 (Control) Sinimamotor. 2017 Total Hierospenker, z [*] _{a} = 93.56 (P < 01, P [*] =	SMD (95% C1) 1.63 [1.20, 2.06] 1.91 (1.91 (7.81, 1.60) -1.40 (2.205, 1.56) < 0.11 (1.0.25; 0.46) 0.21 (0.13, 0.55] 0.61 (0.04; 0.07) 0.61 (0.04; 0.07) 0.61 (0.04; 0.07) 0.61 (0.04; 0.07) 0.71 (0.01; 0.15] 0.71 (0.01; 0.15] 0.71 (0.01; 0.015] 0.71 (0.01; 0.015] 0.71 (0.01; 0.015] 0.71 (0.01; 0.013) 0.71 (0.01; 0.013) 0.71 (0.01; 0.014) 0.71 (0.01; 0.028) 0.71 (0.01; 0.028) 0.71 (0.01; 0.028) 0.71 (0.01; 0.028) 0.71 (0.01; 0.028) 0.71 (0.02; 0.028) 0.71 (0.01; 0.028) 0.71 (0.02; 0.028) 0.71 (0.01; 0.028) 0.71 (0.01; 0.028) 0.71 (0.07; 0.271) 0.61 (0.00; 0.028) 0.71 (0.07; 0.271) 0.61 (0.00; 0.09) 0.71 (0.05; 0.08) 0.71
(C)	Source Patel P 1995 Niemela S. 1996 (Coronary heart disease) Minami J. 2002 Chimienti G. 2003 (CagA(+)) Chimienti G. 2003 (CagA(-)) Sung KC. 2005 Saijo Y. 2005 Caswa H. 2005 Longo-Mberza B. 2007 Yura A. 2007 Kogawa T. 2008 Kucukazman M. 2009 Jia EZ. 2009 Akaoy H. 2009 (Preeclampsia) Akaoy H. 2009 (Preeclampsia) Masummura K. 2011 Kun HL. 2011 Saud Al-Fawaeir. 2013 Yamamoto R. 2013 (Imale) Yamamoto R. 2013 (Imale) Yamamoto R. 2013 (Imale) Yamamoto R. 2013 (Imale) Yateriamaesh J. 2014 (Diabetic) Lu C. 2014 Karpouza A. 2014 Chen TP. 2015 (mine) Chen TP. 2015 (mine) Chen TP. 2015 (dirente) Sun Y. 2016 Shiramoto T. 2017 Total	SMD (95% C1) O01 (-0.18, 0.21) 	(D) Source Nimenia S. 1996 (contor)) Nimenia S. 1996 (contor) Nimenia S. 1996 (contor) heart disea Minarri J. 2002 Chimieri G. 2003 (Cap4(+)) Chimieri G. 2003 (Cap4(+)) Chimieri G. 2003 (Cap4(+)) Sung KC. 2005 Saje Y. 2005 Osawa H. 2005 Diseare B. 2007 Yura A. 2007 Yura A. 2007 Kucukazmam M. 2009 Jia EZ. 2009 Akasy H. 2009 (Preeclampsia) Akasy H.	SMD (95% CI) 1.63 [1 20; 2.06] 1.9 [1.9 [0.78; 1.80] 1.9 [0.78; 1.80] 1.9 [0.78; 1.80] 1.9 [0.78; 1.80] 1.9 [0.78; 1.80] 0.06 [0.01; 0.15] 1.27 [1.53, -0.50] < 0.06 [0.01; 0.15] 1.18 [1.95; 1.42] 0.06 [0.21; 0.45] 0.06 [0.46; 0.87] 0.16 [0.40; 0.28] 0.07 [0.04; 0.09] 0.07 [0.04; 0.09] 0.07 [0.04; 0.09] 0.06 [0.04; 0.05] 0.06 [0.04; 0.05] 0.06 [0.05; 0.08] 0.01 [0.05] 0.05 [0.05] 0.05] 0.05 [0.05; 0.08] 0.01 [0.05] 0.05 [0.05] 0.05] 0.05 [0.05] 0.05] 0.05 [0.05; 0.08] 0.05 [0.05] 0.05] 0.05 [0.0
(C)	Source Patel P. 1995 Numenia S. 1996 (Coronary heart disease) Minama J. 2002 Chrimienti G. 2003 (CagA(+)) Chrimienti G. 2003 (CagA(-)) Sung KC. 2005 Saijo Y. 2005 Saijo Y. 2005 Oiswa H. 2005 Longo-Mhenza B. 2007 Yura A. 2007 Kogawa T. 2008 Kouckazma M. 2009 Jiai EZ. 2009 Akasoy H. 2009 (Oreaclampeia) Akasoy H. 2009 (Oreaclampeia) Chang R. 2011 (CagA(+)) Matsummura K. 2011 Said Al-Fawaeir. 2013 Gerig R. 2013 Yamamok R. 2013 (Gmale) Yamamok R. 2013 (Gmale) Yataeimanesh J. 2014 (Diabateic) Vataeimanesh J. 2014 (Diabateic) Vataeimanesh J. 2014 (Diabateic) Lu C. 2014 Kaspouza A. 2014 Chen TP. 2015 (Gmale) Sun Y. 2016 Cheart P. 2015 (Gmale) Sun Y. 2016 (Cantralos Syndrome X) Rasmi Y. 2016 (Cantralos Syndrome X) Rasmi Y. 2016 (Cantralos Syndromes X) Rasmi Y. 2016 (Cantralos Syndromes X) Paterogenetic; Saig = 535.65 (P < 1), I ² = 64	SMD (95% C1) OOT [0-18: 0.21] 0.06 [-0.29: 0.44] 0.06 [-0.39: 0.22] 0.06 [-0.49: 0.22] 0.07 [0-12: 0.81] 0.06 [-0.69: 0.10] 0.06 [-0.69: 0.10] 0.06 [-0.49: 0.25] 0.06 [-0.49: 0.25] 0.05 [-0.49: 0.25] 0.05 [-0.49: 0.25] 0.05 [-0.49: 0.25] 0.05 [-0.49: 0.25] 0.07 [-0.11: 0.44] 0.07 [-0.14: 0.21] 0.06 [-0.49: 0.25] 0.07 [-0.12: 0.45] 0.07 [-0.05; 0.	(D) Source Nimenia S. 1996 (Control) Nimenia S. 1996 (Control) Nimenia S. 1996 (Control) Nimenia G. 2003 (CapA(+)) Chimienia G. 2003 (CapA(+)) Chimienia G. 2003 (CapA(+)) Sung KC. 2005 Saigo Y. 2005 Saigo Y. 2005 Saigo Y. 2005 Saigo Y. 2005 Assoy H. 2009 (Preeclampsia) Assoy H. 2009 (Preeclampsia) Note H. 2011 (Babetic) Here H. 2011 (Babetic) Assoy H. 2016 (Cantrol) Nimamoto T. 2017 Total Heterogenety, z ₁ [*] = 638.56 (P < .01, P [*] = 1000 (Preeclampsia) Declampsia) Declampsia	SMD (95% C) 1.63 (1 20, 2.06) 1.19 (1 20, 7.05) 1.19 (2 0, 7.05) 0.21 (-0.13, 0.65) 0.21 (-0.13, 0.13) 0.25 (-0.10, -0.05) 0.25 (-0.01, 0.01) 0.25 (-0.01, 0.01) 0.27 (-0.01, 0.0

Fig 2. Forest plots of odds ratio (OR) with 95% confidence interval (CI) showing the effect of *Helicobacter pylori* infection in each lipid profile. The gray box represents an estimate of the OR in the respective studies, and the horizontal line indicates the 95% CI for the respective studies. Diamonds at the bottom represent the pooled estimate of OR. Weights are from fixed-effects metaanalysis. The chi-squared (x^2) test revealed the presence of heterogeneity. The I^2 value shows the extent of heterogeneity. (A) Highdensity lipoprotein cholesterol (HDL-C), (B) low-density lipoprotein cholesterol (LDL-C), (C) total cholesterol (TC), and (D) triglyceride (TG).

https://doi.org/10.1371/journal.pone.0234433.g002

significant association of *H. pylori* infection with the serum lipid profile. In addition, we inspected funnel plots to check the existence of publication bias (S3 Fig). Though asymmetry or small-study effects were detected on all the lipid profiles, no statistically unacceptable results were observed in the tests for publication bias by Macaskill's linear regression method (HDL-C: F(1, 33) = 0.085, P = 0.773, LDL-C: F(1, 25) = 0.243, P = 0.627, TC: F(1, 30) = 0.042, P = 0.840, TG: F(1, 30) = 0.058, P = 0.811).

Discussion

The results of our univariate analyses revealed that *H. pylori* infection has a statistical and clinical relevant relationship with the serum lipid profile (Table 1). Multivariate analyses with AIPW indicated that *H. pylori* infection has significant positive effects on LDL-C and TC and negative effects on HDL-C and TG (Table 2). The possibility of an outlier impacting these results is small because we excluded the participants who were taking lipid-lowering drugs in both the univariate and multivariate analyses. The meta-analysis indicated that *H. pylori* infection is positively associated with LDL-C, TC, and TG and negatively associated with HDL-C with statistical significance. In our meta-analyses, publication bias is an ignorable matter, judging from the results of Macaskill's linear regression method. In addition, the 95% confidence interval overlap in many studies and the estimated effect are in the same direction.

All the results were consistent with that *H. pylori* infection can have a statistically significant effect on the serum lipid profile. Judging from the certainty of the evidence, it is strongly suggested that there is a causal relationship between them. Although interpreting the contradictory association of TG with *H. pylori* infection is difficult, it may be due to the fact that the study participants were generally healthy subjects (free from severe diseases) who underwent annual health check-up. In total, we are now convinced that chronic *H. pylori* infection can lead to increased levels of serum LDL-C and TC and also can lead to a reduced level of serum HDL-C.

These results are noteworthy because both high levels of serum LDL-C and low levels of serum HDL-C are established risk factors of atherosclerosis and coronary artery disease [43]. The rate of *H. pylori* infection has been gradually decreased in Japan, but a similar trend for *H. pylori* infection is observed all over the world. Therefore, it is important to investigate the changing prevalence of *H. pylori* infection along with the serum lipid profile. Results from the present investigation suggest that *H. pylori* infection affects the serum lipid profile and can indirectly influence the various diseases caused by abnormal lipid metabolism. This finding must be clinically important since both *H. pylori* infection and dyslipidemia are very common chronic disorders.

There are some experimental considerations that may have limited this investigation. Because of the cross-sectional study design of this investigation, we were unable to perform accurate analyses of the causal effects. Study participants also completed a comprehensive medical examination, and we could not evaluate the actual conditions of the patients with severe health problems or critical diseases. Also, the serum anti-*H. pylori* antibody test was used to diagnose the presence of *H. pylori*, but it is inferior to a urea breath test or histopathological examination in the quality of infection diagnosis. Finally, there is a limited number of available studies in this field, which could have resulted in a lower-quality of meta-analyses.

Conclusions

Both multivariate analysis using the large-scale data for generally healthy subjects in Japan and meta-analysis based on the previous studies worldwide showed that *H. pylori* infection significantly impacts the serum lipid profile of healthy humans. Since *H. pylori* infection and

dyslipidemia are common disorders worldwide, the significant association between the two is kindly to have clinical utility.

Supporting information

S1 Table. Distributions of the values of HDL-C, LDL-C, TC, and TG categorized based on the status of serum Helicobacter pylori IgG antibody and age groups of males. (XLSX)

S2 Table. Distributions of the values of HDL-C, LDL-C, TC, and TG categorized based on the status of serum Helicobacter pylori IgG antibody and age groups of females. (XLSX)

S3 Table. Estimation of the absolute standardized mean differences before and after matching the respective covariates to compare Helicobacter pylori seropositivity and sero-negativity in generally healthy individuals. (XLSX)

S4 Table. A summary of the characteristics of cohort and case-control studies included in a meta-analysis, which was performed to compare the association of Helicobacter pylori to lipid profile.

```
(XLSX)
```

S5 Table. A summary of the characteristics of cohort and case-control studies excluded in a meta-analysis, which was performed to compare the association of Helicobacter pylori to lipid profile.

(XLSX)

S1 Fig. PRISMA flow diagram. (TIFF)

S2 Fig. The risk of bias summary and graph by the authors' judgments. (A) The risk of bias summary by authors' judgments about each bias element for each study. (B) The risk of bias graph by assessment of the risk of bias across studies. Bias is assessed as judgment (high, low, or unclear) for individual elements. The diagonal stripes show a low risk of bias, pin dot shows unclear risk of bias and black fill shows a high risk of bias. (TIFF)

S3 Fig. Publication bias. (TIFF)

S1 Checklist. (DOCX)

S1 Dataset. (ZIP)

Acknowledgments

We thank Kameda Medical Center Makuhari staffers for great assistance with establishment and maintenance of the study database.

Author Contributions

Conceptualization: Takeshi Shimamoto.

Data curation: Takeshi Shimamoto.

Formal analysis: Takeshi Shimamoto.

Investigation: Takeshi Shimamoto.

Methodology: Takeshi Shimamoto.

Project administration: Nobutake Yamamichi.

Software: Takeshi Shimamoto.

Supervision: Nobutake Yamamichi.

Validation: Takeshi Shimamoto, Kenta Gondo.

Writing - original draft: Takeshi Shimamoto.

Writing – review & editing: Nobutake Yamamichi, Kenta Gondo, Yu Takahashi, Chihiro Takeuchi, Ryoichi Wada, Toru Mitsushima, Kazuhiko Koike.

References

- Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, et al. (2017) Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 153: 420–429. <u>https://doi.org/10.1053/j.gastro.2017.04.022</u> PMID: 28456631
- Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, et al. (2011) Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 20: 299– 304. PMID: 21961099
- Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, et al. (1991) Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325: 1127–1131. <u>https://doi.org/10.1056/</u> NEJM199110173251603 PMID: 1891020
- Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, et al. (1991) Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 325: 1132–1136. https://doi.org/10.1056/NEJM199110173251604 PMID: 1891021
- Franceschi F, Gasbarrini A (2007) Helicobacter pylori and extragastric diseases. Best Pract Res Clin Gastroenterol 21: 325–334. https://doi.org/10.1016/j.bpg.2006.10.003 PMID: 17382280
- Goni E, Franceschi F (2016) Helicobacter pylori and extragastric diseases. Helicobacter 21 Suppl 1: 45–48.
- Kyburz A, Muller A (2017) Helicobacter pylori and Extragastric Diseases. Curr Top Microbiol Immunol 400: 325–347. https://doi.org/10.1007/978-3-319-50520-6_14 PMID: 28124160
- Tarchalski J, Guzik P, Wysocki H (2003) Correlation between the extent of coronary atherosclerosis and lipid profile. Mol Cell Biochem 246: 25–30. PMID: 12841339
- Satoh H, Saijo Y, Yoshioka E, Tsutsui H (2010) Helicobacter Pylori infection is a significant risk for modified lipid profile in Japanese male subjects. J Atheroscler Thromb 17: 1041–1048. https://doi.org/10. 5551/jat.5157 PMID: 20610892
- Kim HL, Jeon HH, Park IY, Choi JM, Kang JS, et al. (2011) Helicobacter pylori infection is associated with elevated low density lipoprotein cholesterol levels in elderly Koreans. J Korean Med Sci 26: 654– 658. https://doi.org/10.3346/jkms.2011.26.5.654 PMID: 21532857
- 11. Haeri M, Parham M, Habibi N, Vafaeimanesh J (2018) Effect of Helicobacter pylori Infection on Serum Lipid Profile. J Lipids 2018: 6734809. https://doi.org/10.1155/2018/6734809 PMID: 29973994
- 12. Klok MD, Jakobsdottir S, Drent ML (2007) The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 8: 21–34. https://doi.org/10.1111/j.1467-789X.2006. 00270.x PMID: 17212793
- Kalra SP, Ueno N, Kalra PS (2005) Stimulation of appetite by ghrelin is regulated by leptin restraint: peripheral and central sites of action. J Nutr 135: 1331–1335. https://doi.org/10.1093/jn/135.5.1331 PMID: 15867335
- Roper J, Francois F, Shue PL, Mourad MS, Pei Z, et al. (2008) Leptin and ghrelin in relation to Helicobacter pylori status in adult males. J Clin Endocrinol Metab 93: 2350–2357. https://doi.org/10.1210/jc. 2007-2057 PMID: 18397989

- Osawa H, Nakazato M, Date Y, Kita H, Ohnishi H, et al. (2005) Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab 90: 10–16. <u>https://doi.org/ 10.1210/jc.2004-1330 PMID: 15483107</u>
- Tatsuguchi A, Miyake K, Gudis K, Futagami S, Tsukui T, et al. (2004) Effect of Helicobacter pylori infection on ghrelin expression in human gastric mucosa. Am J Gastroenterol 99: 2121–2127. <u>https://doi.org/10.1111/j.1572-0241.2004.30291.x PMID: 15554990</u>
- Shiotani A, Miyanishi T, Uedo N, Iishi H (2005) Helicobacter pylori infection is associated with reduced circulating ghrelin levels independent of body mass index. Helicobacter 10: 373–378. https://doi.org/10.1111/j.1523-5378.2005.00343.x PMID: 16181346
- Azuma T, Suto H, Ito Y, Ohtani M, Dojo M, et al. (2001) Gastric leptin and Helicobacter pylori infection. Gut 49: 324–329. https://doi.org/10.1136/gut.49.3.324 PMID: 11511551
- 19. Lopes-Virella MF (1993) Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J 14 Suppl K: 118–124.
- Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, et al. (2004) Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 45: 1169–1196. https://doi.org/10.1194/jlr.R300019-JLR200 PMID: 15102878
- Gallin JI, Kaye D, O'Leary WM (1969) Serum lipids in infection. N Engl J Med 281: 1081–1086. <u>https://</u> doi.org/10.1056/NEJM196911132812001 PMID: 5824173
- Feingold KR, Grunfeld C (2000) The Effect of Inflammation and Infection on Lipids and Lipoproteins. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A et al., editors. Endotext. South Dartmouth (MA).
- Ando K, Shimamoto T, Tauchi T, Ito Y, Kuriyama Y, et al. (2003) Can eradication therapy for Helicobacter pylori really improve the thrombocytopenia in idiopathic thrombocytopenic purpura? Our experience and a literature review. Int J Hematol 77: 239–244. <u>https://doi.org/10.1007/BF02983780</u> PMID: 12731666
- Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D (2007) Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother 60: 237–246. https://doi.org/10.1093/jac/dkm195 PMID: 17561502
- Luther J, Dave M, Higgins PD, Kao JY (2010) Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Inflamm Bowel Dis 16: 1077–1084. https://doi.org/10.1002/ibd.21116 PMID: 19760778
- 26. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, et al. (2011) Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardio-vascular disease. Ann Rheum Dis 70: 482–487. https://doi.org/10.1136/ard.2010.135871 PMID: 21216812
- Robertson J, Peters MJ, McInnes IB, Sattar N (2013) Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9: 513–523. <u>https://doi.org/10.1038/nrrheum.</u> 2013.91 PMID: 23774906
- Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Nurmohamed M (2014) Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 53: 2143–2154.
- The results of the 2014 Patient Survey are available on the website of Ministry of Health, Labour and Welfare (http://www.mhlw.go.jp/english/database/db-hss/dl/sps_2014_01.pdf, February. 15, 2017).
- Smith DG (2007) Epidemiology of dyslipidemia and economic burden on the healthcare system. Am J Manag Care 13 Suppl 3: S68–71.
- Annual Health, Labour and Welfare Report 2007–2008—Measures against Lifestyle related Diseases through "Health Japan 21" and Promotion of "Shokuiku(food and nutrition education)" (Health,Labour and Welfare Ministry, <u>https://www.mhlw.go.jp/english/wp/wp-hw2/part2/p2c1s3.pdf</u>, February. 18, 2017).
- Annual Health, Labour and Welfare Report 2008–2009–2. Health and Medical Services—Specific Health Checkups and Specific Health Guidance (Health,Labour and Welfare Ministry, https://www. mhlw.go.jp/english/wp/wp-hw3/dl/2-007.pdf, February. 18, 2017).
- **33.** Questionnaire on specific health examination (AMDA International Medical Information Center, http://eng.amda-imic.com/oldpage/amdact/PDF/eng/spe-he-ex-e.pdf, May. 12, 2020).
- Little RJ, Rubin DB (2000) Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health 21: 121–145. https://doi.org/10.1146/ annurev.publhealth.21.1.121 PMID: 10884949
- 35. Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, et al. (2007) Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival

using propensity score and instrumental variable methods. JAMA 297: 278–285. https://doi.org/10. 1001/jama.297.3.278 PMID: 17227979

- Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, et al. (2001) Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 54: 387–398. <u>https://doi.org/10.1016/s0895-4356(00)00321-</u> 8 PMID: 11297888
- Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, et al. (1995) Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 311: 711–714. https://doi.org/10.1136/bmj.311.7007.711 PMID: 7549683
- Niemela S, Karttunen T, Korhonen T, Laara E, Karttunen R, et al. (1996) Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart 75: 573–575. https://doi.org/10.1136/hrt.75.6.573 PMID: 8697159
- Saijo Y, Utsugi M, Yoshioka E, Horikawa N, Sato T, et al. (2005) Relationship of Helicobacter pylori infection to arterial stiffness in Japanese subjects. Hypertens Res 28: 283–292. https://doi.org/10. 1291/hypres.28.283 PMID: 16138557
- Macaskill P, Walter SD, Irwig L (2001) A comparison of methods to detect publication bias in meta-analysis. Stat Med 20: 641–654. https://doi.org/10.1002/sim.698 PMID: 11223905
- Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, et al. (2013) Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 66: 408–414. https://doi.org/10.1016/j.jclinepi.2012.09.016 PMID: 23337781
- 42. Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14: 135. https://doi.org/10.1186/1471-2288-14-135 PMID: 25524443
- 43. Mahmood SS, Levy D, Vasan RS, Wang TJ (2014) The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet 383: 999–1008. <u>https://doi.org/10.1016/S0140-6736(13)61752-3 PMID: 24084292</u>